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ABSTRACT
THE RELATIONSHIP OF METABOLIC CONTROL TO HARDINESS, SELF- 
EFFICACY, AND PERCEIVED MEDICATION ADHERENCE IN ADULTS WITH 
DIABETES MELLITUS
By Ok Chon Pyon Allison, Ph.D., APRN, BC, ANP
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2003.
Major Director: Janet B. Younger, Ph.D., R.N., P.N.P., Professor and Associate Dean, 
School of Nursing, Virginia Commonwealth University
Diabetes mellitus, a serious and costly disease, is a public health challenge. 
Diabetes is controllable, yet non-adherence to prescribed medications causes diabetes- 
related complications resulting in hospital admissions and readmissions that may be 
prevented. A cross-sectional, descriptive-correlational study was conducted to 
investigate the relationship of metabolic control (A1C) to hardiness, self-efficacy, and 
perceived medication adherence. Health-Related Hardiness Scale (Pollock, 1990); 
Long-Term Medication Behavior Self-Efficacy Scale (De Geest et al., 1994); and 
Perceived Medication Adherence Scale (Allison, 2000) were administered to 215 
participants. Data analyses of correlation and multiple linear regression using SPSS
10.0 statistical software were performed. Metabolic control was not significantly 
predicted by hardiness, self-efficacy, and perceived medication adherence. However,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
42% (n = 88) had A1C level < 7%. The Perceived Medication Adherence Scale was 
found to be of one factor structure and reliable. The findings indicate that physiological 
phenomena were not predicted by self-reported behavioral phenomena. Further 
research using an intervention study, such as patient education and/or telephone follow- 
up intervention in conjunction with diet and medication therapy needs to be conducted 
to determine whether metabolic control will be improved in adults with diabetes 
mellitus.
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Chapter I: Introduction
Diabetes mellitus is a serious and complex disease. If left uncontrolled, diabetes 
can cause many complications — both microvascular (blindness as a result of retinopathy, 
end-stage renal disease, peripheral neuropathy, and non-traumatic lower-extremity 
amputations) and macrovascular complications (ischemic heart disease, stroke, and 
peripheral vascular disease). A high death rate from cardiovascular causes is due to high 
levels of risk factors for heart disease in individuals with diabetes. These risk factors are 
elevated fasting plasma glucose, blood pressure, cholesterol, triglycerides, obesity and 
cigarette smoking (Harris, 1998).
Despite the pending complications, patients with diabetes are often nonadherent 
(Kurtz, 1990). Adherence to the diabetes regimen varies from 7% in all aspects of the 
regimen (Cerkoney & Hart, 1980); 20% adherence with insulin injections (Watkins, 
Roberts, Williams, Martin & Coyle, 1967); to 57% (Cerkoney & Hart, 1980) to 70% of the 
monitoring regimen (Hopkins, Alford, Handelsman, Yue & Turtle, 1988). Nonadherence 
to the prescribed medication leads to poor diabetic control and infection, which are the 
cause of frequent hospital admissions and readmissions (Glasgow, McCaul & Schafer, 
1987; Fishbein, 1985; Morris et al., 1997; Thompson, Cummings, Chalmers & Newton, 
1995).
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2In a meta-analysis of 17,703 patients taking various medications for different 
medical conditions on a long-term medication regimen for treatment or cure, it was 
found that 50% of the patients did not take prescribed medications as instructed 
(Sackett & Snow, 1979; Wright, 1993). About 43% of the elderly population in a study 
were found to be prescription drug non-compliant for various reasons, including 
decreased comprehension and visual acuity, and inadequate labeling and medication 
changes (Kendrick & Bayne, 1982). A self-report survey of 341 female patients having 
diabetes who were 16 to 60 years of age found that insulin omission was common — 
31% of the female subjects reported intentional insulin omission and 8.8% reported 
frequent omission (Polonsky et al., 1994). The practices of insulin injection and 
decision-making on insulin therapy among 100 persons, ages ranging from 17 to 64, 
with type 1 diabetes were studied. The study participants were asked a few open-ended 
questions and it was found that 31% of the study participants were skipping insulin 
injections for reasons varying from forgetfulness to intentional omission (Partanen & 
Rissanen, 2000). Poor compliance with insulin therapy in young insulin dependent 
diabetic patients was the major contributing factor to long-term poor glycemic control 
and diabetic ketoacidosis and, therefore, to increased hospital admissions (Morris et al., 
1997; Thompson et al., 1995).
A 3-year retrospective case note review of all patients (N = 84) admitted with 
ketoacidosis to Ninewells Hospital between January 1991 and December 1993 found 
that non-adherence to the insulin regimen was 42% in young adult patients with hospital
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3admission for ketoacidosis (Thompson et al., 1995). In another study, 27% of the 
patients having diabetes had a specific educational deficit that was responsible for their 
hospitalization (Geller & Butler, 1981). Thus, from the literature, it can be seen that 
patients with diabetes have compliance problems with prescribed regimens like other 
patients with chronic illnesses.
Purpose
The purpose of the study was to investigate the relationships between the 
response variable, A1C (metabolic control), and three predictor variables (hardiness, 
self-efficacy, and perceived medication adherence) in adults with diabetes mellitus. 
Also, the Perceived Medication Adherence Scale used for this study was examined for 
further refinement, and retainment of factor structure and psychometric properties. The 
findings may become an impetus to conduct an experimental study in the future to 
determine how to improve management and control of diabetes.
Background and Significance
The prevalence of diabetes mellitus is increasing. It poses a significant public 
health challenge in terms of morbidity, mortality, and economic impact in the United 
States.
Prevalence
There are about 17 million (11.1 million people are diagnosed, and 5.9 million 
people are yet to be diagnosed) Americans - 6.2% of the population - who have diabetes 
(CDC, National Diabetes Fact Sheet, n.d., Retrieved February 23. 2003).
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4About 800,000 new cases are diagnosed each year, or 2,200 cases per day (Clark, 1998; 
Burke et al., 1999). Trends show that minority populations are disproportionately 
affected by diabetes. Between 1980 to 1999, the prevalence of diabetes was greater 
among blacks than whites; the age-adjusted prevalence was highest among black 
females (CDC, Statistics: Diabetes Surveillance System, n.d., Retrieved March 16, 
2003). See Figure 1.
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Figure 1. Age-Standardized Prevalence of Diagnosed Diabetes by Race/Ethnicity 
and Sex, United States, 1980-1999, CDC, Statistics: Diabetes Surveillance System, n.d., 
Retrieved March 16, 2003.
When age-specific prevalence of diagnosed diabetes by race/ethnicity and sex 
was examined, Black women had the highest prevalence among those aged less than 75 
years and Hispanic men and women had the highest prevalence among those aged 75
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5years and older (CDC, Statistics: Diabetes Surveillance System, n.d. Retrieved March 
16, 2003). See Figure 2.
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Figure 2. Age-Specific Prevalence of Diagnosed Diabetes, by Race/Ethnicity and Sex, 
United States, 1999, CDC, Statistics: Diabetes Surveillance System, n.d., Retrieved 
March 16, 2003)
Morbidity
Uncontrolled diabetes can cause infection, increased hospital admission and 
readmission. It further complicates the disease process affecting multi-organ systems. 
Heart disease is the leading cause of diabetes-related deaths; risk of stroke is 2 to 4 
times higher in people with diabetes. High blood pressure is prevalent in 60% to 65% 
of people with diabetes. Blindness is caused by diabetes, which is the leading cause of 
new cases of blindness in adults 20 to 74 years old. Diabetic kidney disease causes end-
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6stage renal disease requiring dialysis or kidney transplant. Diabetes causes nervous 
system disease (impaired sensation or pain in the extremities, gastroparesis, carpal 
tunnel syndrome, etc.). The major contributing cause of lower extremity amputation is 
severe diabetic neuropathy (stepping on a nail leads to a nonhealing wound and then to 
amputation). Periodontal disease occurs with greater frequency and severity among 
people with diabetes. Complication of pregnancy contributes to congenital 
malformations in babies when preconception care is not received. Other devastating 
complications are diabetic ketoacidosis and hyperosmolar nonketotic coma that require 
hospitalizations. People with diabetes are more susceptible to and more likely to die of 
pneumonia or influenza than people without diabetes (CDC, National Diabetes Fact 
Sheet, n.d., Retrieved February 23, 2003). Diabetes was one of the top three recorded 
causes of 887,000 emergency room visits and one of three diagnoses for almost 2.2 
million hospital outpatient visits in 1992 (Environmed Research Inc., 1999).
Type 2 diabetes mellitus may be the most rapidly growing chronic disease in the 
world (Nathan, 1995). Insulin resistance, a major cause of type 2 diabetes, is a 
condition of reduced sensitivity in both hepatic and peripheral tissues to the action of 
endogenous insulin (American Diabetes Association [ADA], 1998). Insulin resistance 
is strongly associated with obesity (Chatteijee & Scobie, 2002), defined as a Body Mass 
Index > 27 kg/m (ADA, 1998). Insulin resistance is also known as syndrome X, or 
metabolic syndrome. It includes glucose intolerance leading to type 2 diabetes, 
hypertension, low HDL cholesterol, and elevated triglyceride levels leading to
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7atherosclerosis (Gavin, 2001), and obesity. One out of every four people in the U.S., 
(80 million Americans) have insulin resistance thereby increasing the risk for heart 
disease (The apple figure & insulin sensitivity, n.d., Retrived April 2, 2003). 
Furthermore, 80% of people with type 2 diabetes are either overweight or obese 
(Prescatore, 2003).
Mortality
Diabetes mellitus is a serious chronic disease that can cause premature death if 
uncontrolled. Diabetes is the 5th leading cause of death by disease in the U. S. 
(American Diabetes Association, 2003). The age-adjusted death rate was 13.5 deaths 
per 100,000 population in 1997. Diabetes was the seventh leading cause of death in the 
United States in 1997 (National Vital Statistics Reports, 1999). It was the sixth leading 
cause of death listed on U. S. death certificates in 1999 (CDC, National Diabetes Fact 
Sheet, n.d., Retrieved February 23, 2003). The crude and age-adjusted death rate was 
19.4 deaths per 100,000 people in Virginia in 1998. Also, diabetes was the seventh 
leading cause of death in the Commonwealth of Virginia in 1998. The age adjusted 
death rate rose from 12.2 deaths per 100,000 population in 1940 to 21.8 deaths per
100,000 population in 2000 (Virginia Department of Health, 2000).
Economic Impact
Diabetes management is costly. Approximately $1 of every $6 - $7 spent on 
health care in the United States is spent on diabetes. Further, $1 of every $4 spent by 
Medicare on health care is spent on people with diabetes (Clark, 1998).
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8Total costs (direct and indirect) of diabetes in the United States in 2002 were estimated 
at $132 billion. Direct medical expenditures totaled $91.8 billion ($23.2 billion for 
diabetes care, $24.6 billion for chronic complications attributable to diabetes and over 
$44 billion for excess prevalence of general medical conditions [43.9% inpatient days 
and 15.1% nursing home, and 19.9% office visits]). Indirect expenditures totaled $39.8 
billion resulting from lost workdays, restricted activity days, mortality, and permanent 
disability due to diabetes (American Diabetes Association, 2003).
Treatment of diabetic complications consumes a tremendous amount of health 
care resources. "From the perspective of a single-payer national health system, it was 
estimated that blindness costs approximately $2,000 per person per year in direct 
medical costs, end-stage renal disease costs approximately $45,000 per patient per year, 
and amputation costs approximately $31,000 per patient per episode" (Herman & 
Eastman, 1998, p. C21).
Diabetes mellitus is a serious and complex disease, but with intensive therapy it 
can be controlled and the rate of development and complications can be slowed. The 
Diabetes Control and Complication Trial (DCCT) Research Group (1993) reported that 
intensive insulin therapy for patients with insulin dependent diabetes (type 1 diabetes) 
reduced microvascular risk factors (retinopathy by 76%, nephropathy by 39% and 
neuropathy by 60%). The "Kumamoto" study revealed that intensive glycemic control 
by multiple insulin injection therapy delayed the onset and the progression of diabetic 
complications (retinopathy by 69% and nephropathy by 70%) in noninsulin dependent
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
9(type 2) diabetic patients (Ohkubo et al., 1995). Patients with type 2 diabetes mellitus 
had improved blood glucose levels and reduced complications with intensive therapy 
with metformin, sulphonylurea or insulin (The United Kingdom Prospective Diabetes 
Study [UKPDS], 1995). The intensive treatment (sulphonylurea or with insulin, or 
conventional policy with diet) group had a 25% reduction in the risk of microvascular 
endpoint and a 16% risk reduction (p = 0.052) for myocardial infarction, including non- 
fatal and fatal myocardial infarction and sudden death. However, diabetes-related 
mortality and all-cause mortality did not differ between the intensive and conventional 
groups (UKPDS, 1998).
Empirically, there are knowledge gaps in ways to remedy the problems of non­
adherence to the diabetes regimen (Watkins, Roberts, Williams, Martin, & Coyle, 1967; 
Polonsky et al., 1994; Partanen & Rissanen, 2000). Regimen non-adherence caused 
poor diabetic control and acquisition of infection that led to hospitalizations (Glasgow, 
McCaul, & Schafer, 1987; Fishbein, 1985; Morris et al., 1997; Thompson, Cummings, 
Chalmers & Newton, 1995) and long term complications (Harris, 1998). These findings 
are focused on finding non-adherent behaviors, rather than comprehensive solutions.
The multi-center trials of DCCT (1993) and UKPDS (1995) showed that intensive 
hypoglycemic medication therapies reduced diabetes related complications. However, 
published evidence of a cross-sectional descriptive correlational study being conducted 
at small clinic settings looking for the relationship between one dependent variable,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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metabolic control (A1C), and the three predictor variables (hardiness, self-efficacy and 
medication adherence) with adults having diabetes was not found.
Conceptual Definitions
Adherence
For the purpose of this study, adherence will be used. Adherence is defined as 
“the process in which a person follows rules, guidelines, or standards, especially as a 
patient follows prescription and recommendations for a regimen of care” (Mosby’s 
Dictionary, 1990, p. 27). Also, adherence is defined as “the degree to which a patient 
follows a predetermined set of behaviors or actions (established cooperatively by the 
patient and provider) to care for diabetes on a daily basis” (McNabb, 1997, p. 217). 
Some of the literature uses the word compliance. Compliance is defined as "the extent 
to which a person's behavior (in terms of taking medications, following diets or 
executing lifestyle changes) coincides with medical or health advice" (Haynes, 1979, p. 
1 -2). Thus, the word compliance may be considered interchangeably with the 
adherence.
Medication Adherence
Medication adherence is adherence with prescribed medication regimens. This 
concept has three dimensions, self-care, self-efficacy and decision-making (Allison, 
2000).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Self-Care. Self-care is the voluntary practice of activities that enables 
individuals to maintain life, health, and well being in a variety of states or to move from 
one state to another (Orem, 1995).
Self-Efficacy or Perceived Self-Efficacy. Self-efficacy is a central concept in 
Bandura's Social Cognitive Theory (Social Learning Theory) and it is defined as 
"people's judgments of their capabilities to organize and execute courses of action 
required to attain designated types of performances. It is concerned not with the skills 
one has but with judgments of what one can do with whatever skills one possesses" 
(Bandura, 1986, p. 391). Perceived Self-Efficacy is the estimation of a person's own 
efficacy. For the purpose of this study, perceived self-efficacy and self-efficacy are 
used interchangeably.
Decision-making. Decision-making is the process of deciding or making up 
one's mind for health promotion in this study.
Hardiness
Hardiness is defined as a personal constellation of attitudes, beliefs, and 
behavioral tendencies that consist of commitment, control and challenge (Lambert & 
Lambert, 1999).
Commitment. Hardy persons have an ability to feel deeply involved or 
committed to the activities of their lives (Kobasa, 1979). Appraisal and coping lead to 
involvement in health-related activities appropriate for dealing with the health stressors 
(Pollock, 1989a).
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Challenge. Hardy persons see change as an exciting challenge for further 
development (Kobasa, 1979). Reappraisal of health stressors is potentially beneficial 
(Pollock, 1989a).
Medication Behavior Self-Efficacy
Medication behavior self-efficacy includes concepts used in the development of 
the long-term medication behavior self-efficacy scale that is based on Bandura's 
conceptualization of dimensions of self-efficacy (De Geest, Abraham, Gemoets, and 
Evers, 1994). The concepts used in the scale are personal attributes, environmental 
factors, and task related and behavioral factors.
Personal Attributes. Personal attributes are comprised of four themes. The 
themes are emotional distress, confidence in the physician, perceived health status, and 
normalcy.
Environmental Factors. Environmental factors consist of the themes of routine, 
distraction, social support and cost of medication.
Task-Related and Behavioral Factors. Task-related and behavioral factors are 
composed of the themes of side effects, drug delivery system, medication aids, 
medication schedule, and knowledge.
Metabolic Control
Metabolic control refers to glycemic status, or glucose level in the blood, which 
indicates the degree of diabetes control.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Overview o f the Study
Diabetes mellitus is an increasingly common and serious chronic disease that 
poses a threat to individuals' health, finances and quality of life. Diabetes is a 
controllable disease, yet nonadherence with an appropriate hypoglycemic regimen 
causes an increase in morbidity and mortality. Diabetes-related complications cause 
hospitalization that may be prevented by education interventions. This study is a 
descriptive-correlational study investigating the relationship of metabolic control to 
hardiness, self-efficacy, and perceived medication adherence. The value of metabolic 
control was obtained by accessing the laboratory value of A1C, which was measured 
every visit the patient made to the diabetes and primary care clinics.
To measure some characteristics of persons with diabetes and their medication 
adherence and management behaviors, demographic data (Appendix A) were obtained, 
then, three scales were administered. The patients completed Health-Related Hardiness 
Scale (Appendix B) by Pollock (1986; Pollock & Duffy, 1990; Pollock, Christian, & 
Sands, 1990), and the Long-Term Medication Behavior Self-Efficacy Scale (Appendix 
C) by De Geest et al. (1995) to determine if high self-efficacy was related to metabolic 
control in participants' long-term medication regimens. Finally, the Perceived 
Medication Adherence Scale (Allison, 2000; Appendix D) was administered to 
determine how well the research participants practice their prescribed hypoglycemic 
medication adherence.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Surveys were stored in a locked filing cabinet accessible only to this co­
investigator. Data were entered by this co-investigator manually. The design of the 
study was non-experimental, cross-sectional, descriptive-correlational study. For data 
analysis, correlation and multiple linear regressional analyses using SPSS 10.0 
statistical software were performed.
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Chapter II: Conceptual Framework
The conceptual framework for this study is presented in Figure 3. Unless adults 
with diabetes feel in control of their disease, managing diabetes can be stressful and it 
may not be controlled. A hardy personality type may influence day-to-day diabetes 
management decisions. Which personality constellation influences hypoglycemic 
medication adherence, and the level of adaptation as well as the role of self-efficacy in 
the management of diabetes needed to be determined. Once the medical providers 
know the pattern of medication adherence of their patients with diabetes, metabolic 
control will be predictable. The conceptual framework for this study was based on the 
concept of hardiness by Kobasa (1979), and health-related hardiness by Pollock (1986) 
in conjunction with her adaptation to chronic illness model (Pollock, 1989a), long-term 
medication behavior self-efficacy by DeGeest et al. (1994), self-efficacy concept by 
Bandura (1977), and perceived medication adherence based on Orem's Self-care (Orem, 
1995).
15
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Metabolic Control
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Figure 3. Conceptual Framework of Metabolic Control in Persons with Diabetes
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Hardiness Concept
The concept of hardiness as a personality characteristic was developed by 
Kobasa (1979). Hardiness is a constellation of personality characteristics that function 
as a resistance resource in the encounter with stressful life events. According to Kobasa 
(1979), when people experience a high degree of stress, some fall ill, and some 
overcome the adversity by transforming themselves to cope with the situation and do 
not fall ill. Persons who can cope with the adversity and stay healthy have the 
personality characteristic of hardiness. Hardy persons possess three general 
characteristics: commitment, control, and challenge. They have the ability to feel 
deeply involved in or committed to the activities of their lives and anticipate change as 
an exciting challenge to further development. Persons low in hardiness might 
exaggerate constitutional predispositions by engaging in negative health practices - 
overeating and overdrinking (Kobasa, Maddi, & Kahn, 1982). Hardy persons believe 
that they can control or influence the events of their experience, and yet, when they 
recognize their inability to control the events, they ask others for help, thereby keeping 
the events under control. Kobasa (1979) developed three hypotheses related to health 
and illness. Among persons under stress: (a) Those who have a greater sense of control 
over events in their lives will remain healthier than those who feel powerless when 
facing external forces, (b) those who feel committed to the various areas of their lives 
will remain healthier than those who are alienated, and (c) those who view change as a 
challenge will remain healthier than those who view it as a threat.
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On the basis of 670 completed stress and illness questionnaires from public 
utility male executives (middle and upper level), Kobasa (1979) asserts that hardiness is 
confirmed by the study. High stress/low illness executives are: (a) more in control, 
more committed, and more oriented to challenge than are high stress/high illness 
executives; (b) distinguished by their sense of commitment to (not alienated from) self, 
their sense of vigorousness and sense of meaningfulness and locus of control in life; and 
(c) viewing themselves as having less stress than high stress/high illness executives do. 
Results of Kobasa's study postulate that personality may have something to do with 
staying healthy. Further, hardiness has its greatest health-preserving effect when 
stressful life events mount (Lambert & Lambert, 1987).
Health-Related Hardiness (HRH):
The concept of HRH was developed on the basis of Roy's adaptation model, 
Kobasa's hardiness characteristics, Pollock's adaptation to chronic illness, and Lazarus' 
work on the concept of coping:
The "health-related hardiness framework postulates that, when a hardy person is 
confronted with a health stressor, he or she possesses the confidence and self- 
mastery to appraise and modify responses appropriately (control). The 
framework, also, cognitively reappraises the health stressor so that it is viewed as 
stimulating and beneficial or an opportunity for growth (challenge), which, in 
turn, is evidenced by motivation and competence in promoting his or her health
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and coping with the health stressor (commitment)" (Pollock, 1999, p. 1).
Persons are challenged (rather than threatened) when confronted with a health stressor, 
which in turn, becomes a personal commitment. Hardy individuals dealing with a 
chronic health problem may not separate health into discrete categories but appraise the 
condition as a challenge, because they are committed to maintaining their health. 
Adaptation to Chronic Illness
Adaptation to chronic illness is based on the integration of the major variables of 
chronicity, stress, hardiness, and physiological and psychosocial adaptation. The 
integration process is complex, and one is expected to go through both internal and 
external processes to achieve one's physiological and psychosocial adaptation to the 
chronic illness (Pollock, 1986), such as diabetes. The presence of the hardiness 
characteristic was significantly correlated with physiological adaptation in patients with 
diabetes (Pollock, 1986). Pollock (1989a) developed the moderating effect of hardiness 
(Figure 4) on adaptation to the chronic illness framework.
"Hardiness may indirectly affect adaptation to chronic illness by influencing the 
individual's perception of the stressor (chronic illness), the coping strategies chosen, or 
the social resources used" (p. 59). Unlike Kobasa, Pollock pointed out that an 
individual's perception and use of social resources were significantly related to the 
presence of hardiness in healthy adults.
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Figure 4. Moderating Effect of Hardiness (Indirect). Reprinted with permission 
(Appendix E) from Pollock, S. E.: The hardiness characteristic: A motivating factor in 
adaptation, 1989a.
Long-Term Medication Behavior Self-Efficacy
Self-Efficacy. Perceived self-efficacy is the central concept of the social 
cognitive theory by Bandura (1977). Expectations of personal efficacy (self-efficacy) 
“determine whether coping behavior will be initiated, how much effort will be 
expended, and how long it will be sustained in the face of obstacles and aversive 
experiences” (p. 191). Self-efficacy beliefs function as important determinants of 
human motivation, affect, and action (Bandura, 1989). Perceived self-efficacy proved 
to be an accurate predictor of performance in the inactive mode of treatment although 
subjects were engaged in no overt behavior. Also, it proved to be a better predictor of
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behavior toward unfamiliar threats than did past performance (Bandura, 1977). Further, 
“perceived self-efficacy influenced performance both directly and through its strong 
effect on personal goal setting. Personal goals, in turn, enhanced organizational 
attainments directly and by means of the mediation of analytic strategies” (Bandura & 
Wood, 1989, p. 813). Therefore, the higher the level of one’s self-efficacy, the higher 
the performance accomplishments and the lower the emotional arousal expected 
(Bandura, 1982) because those who have a high sense of self-efficacy visualize success 
scenarios that provide positive guides for performance (Bandura, 1989).
Understanding and promoting medication adherence are vital areas in nursing 
practice. The Long-Term Medication Behavior Self-Efficacy Scale (Appendix C) was 
developed by De Geest, Abraham, Gemoets and Evers (1994) based on Bandura's 
conceptualization of dimensions of self-efficacy. Dimensions and attributes of the scale 
are composed of:
1. Personal attributes with the themes of emotional distress, confidence in the 
physician, perceived health status, and normalcy affect the precision of medication 
intake.
2. Environmental factors include the themes of routine, distraction, social 
support and cost of medication influence medication-taking behavior.
3. Task-related and behavioral factors are composed of the themes of side 
effects, drug delivery system, medication aids, medication schedule, and knowledge.
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Medication Adherence
Medication adherence is a health promoting behavior that is achieved when an 
individual practices self-care. Orem’s Self-Care Deficit model relates medication 
adherence as a self-care activity in individuals with diabetes. The word, deficit, stands 
for the relationship between the action individuals should take and the action 
capabilities of individuals for self-care or dependent-care. “Deficit in this context 
should be interpreted as a relationship, not as a human disorder” (Orem, 1995, p. 177). 
Self-care is a learned activity and it is an action of mature and maturing individuals who 
are responsible and capable of performing the needed care deliberately or voluntarily, 
for themselves to maintain life, health and well being of their whole being. This, in 
turn, will affect their human functioning, human development, and human structural 
integrity (Orem, 1995).
To promote health, individuals play a critical role in the determination of their 
own health status. Every day, they make decisions that form lifestyle, social and 
physical environments. Health promotion at the individual level improves decision­
making, and practicing health thereby improves self-care, which is the main mode of 
individual health care (Pender, 1996). Orem (1995) describes health as the state of 
wholeness (structurally and functionally). It also includes psychological, physical, 
interpersonal, and social aspects of living. In order for individuals to manage and keep 
diabetes under control, they must be motivated and responsible for medicating
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themselves in fulfilling their self-care responsibilities in terms of adhering to the 
hypoglycemic medication(s) prescribed to them. To enhance the subject’s self-care 
practice, Orem’s self-care theory is appropriate for the development of the adult 
diabetes support group and diabetes education (Morris, 1998).
Medication adherence also requires individual decision-making strategies to 
promote health. There are four decision-making strategies that are conceptualized by 
Janis and Mann (1977). These are:
Optimizing and the perils o f suboptimizing. "When an individual makes a vital 
decision bearing on his career, marriage, or health or on any other aspect of his personal 
welfare, he does not think only about the major utilitarian goals to be attained. He also 
takes account of a multiplicity of intangible considerations bearing on the probable 
effects of the chosen and unchosen courses of action on relatives and friends" (p. 24- 
25). The person's self-esteem with regard to living up to his personal standards of 
conduct also affects his decision-making.
Satisfying. This strategy is meeting a "good enough" outcome (minimal 
requirements).
Mixed scanning. To features of the optimizing strategies combined with 
essential features of the elimination-by-aspects approach and an incremental process 
approach followed for the minor decisions, ensue after the basic desired direction is set. 
This strategy is involved in the main cognitive activities, "vigilant information 
processing."
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The decision-maker's repertoire. Every decision-maker has in his repertoire 
a variety of substrategies and orientations, and he uses the strategy deemed effective for 
the situation at that particular moment (Jannis & Mann, 1977).
Metabolic Control
Hemoglobin A ic (A1C) is the biochemical test that is used for this study as the
index of metabolic control. Erythrocytes are freely permeable to glucose and their 
average life span is 120 days. The level of AIC in a blood sample provides a glycemic 
history of the previous 120 days, the average erythrocyte life span, thus reflecting the 
previous 2-3 months of glycemic control.
Theory o f the Study
The dependent variable of the study is the metabolic control of the biochemical 
measure, AIC. Predictor variables are hardiness, self-efficacy, and perceived 
medication adherence. Cofactor variables are demographics (age, education, and race) 
and disease situation (comorbid chronic illness, diabetes medications and duration of 
diabetes).
Adults with diabetes must make constant decisions on monitoring and 
management in order to control their chronic illness and to avoid the development of 
diabetes related complications. This includes adherence to their prescribed regimen, 
especially hypoglycemic medication. Hardiness characteristics, self-efficacy, and 
perceived hypoglycemic medication adherence are considered very important variables
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that contribute to prescribed hypoglycemic medication adherence. Therefore, adults 
with diabetes who are hardy and/or who have self-efficacy (while controlling for 
demographics and disease situation) will be more likely to practice hypoglycemic 
medication adherence thereby achieving metabolic control. However, the relationship 
between hardiness characteristics and self-efficacy has not yet been established. 
Therefore, it is reasonable to test perceived medication adherence practice by 
administering scales that test hardiness, self-efficacy, and perceived medication 
adherence to obtain answers. See Figure 5.
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Figure 5. Theoretical Framework of Improved Metabolic Control
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Achievement o f Metabolic Control
Metabolic control can be achieved when adults with uncontrolled diabetes adhere 
to their prescribed regimens (hypoglycemic medications), when diet and exercise do not 
control their condition. AIC is a biochemical test that monitors the degree of metabolic 
control. The usefulness of AIC is further explored below.
AIC.  The glycohemoglobin test is a useful test in assessing trends in response to 
therapy because it measures a patient's average glycemia over the preceding 2-3 months. 
The American Diabetes Association recommends that AIC testing should be performed 
routinely in all patients with diabetes at the initial visit to document the existing degree 
of glycemic control and approximately every 3 months thereafter for continuous care. 
For those patients who meet treatment goals, AIC should be performed at least two 
times a year. AIC should be performed quarterly in patients whose therapy has 
changed and in patients who are not meeting glycemic goals, in conjunction with the 
judgment of the clinician. AIC is a valuable tool for monitoring glycemia, but it is not 
currently recommended for the screening or diagnosing of diabetes (ADA, 2003). 
Depending on the assay method and laboratory used, the test may be called Hemoglobin 
AIC (AIC),Hemoglobin A], glycohemoglobin, glycated hemoglobin (GHb), or 
glycosylated hemoglobin. Glycated hemoglobin is expressed as a percentage (%) of 
total hemoglobin — the fraction of total hemoglobin that has glucose attached.
Although the different measurements and different assay methods produce different
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normal ranges, when properly performed, the readings correlate closely with each other. 
Though it is not used as a test for the diagnosis, AIC measurement improves the 
sensitivity of screening in high-risk individuals (Perry et al., 2001). Currently, efforts 
are underway to standardize the various assay methods world wide (American Diabetes 
Association, 1998). The combination of fasting plasma glucose (FPG) and AIC is 
recommended because it is more predictive than either parameter alone (Perry et al., 
2001).
Measurement of AIC complements self-monitoring of blood glucose (SMBG) 
predictively and objectively. Discrepancies between SMBG and AIC results are 
considered more commonly due to problems with SMBG (Bardin, 1997). When AIC 
determinations are inconsistent with SMBG reports, concerns include the following: (a) 
The patient is misusing the SMBG equipment, (b) the patient is using a faulty or 
uncalibrated meter or (c) the patient is providing inaccurate data (ADA, 1998).
Metabolic control can be achieved and diabetes-related complications can be 
decreased with intensive management of diabetes. The Diabetes Control and 
Complications Trial (DCCT) research group found that patients with type 1 diabetes 
receiving intensive therapy had decreased diabetes-related complications — for every 
percentage decrease in glycated hemoglobin (AIC), there was a 25% decrease in 
diabetes-related deaths, a 7% decrease in mortality, and an 18% reduction in combined 
fatal and nonfatal myocardial infarction (Nicollerat, 2000). Further, the DCCT results 
indicate that the rate of progression of retinopathy is correlated with mean AIC levels;
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successful efforts in lowering AIC corresponds with the lowering of the rate of 
complications. The United Kingdom Prospective Diabetes Study (UKPDS) group 
results showed that intensive therapy improves glucose control and reduces 
complications of persons with type 2 diabetes. The incidence of clinical complications 
was significantly associated with metabolic control as revealed in the UKPDS 35 
prospective observational study. Each 1% reduction in updated mean AIC was 
associated with reductions in risk of 21% for any end point related to diabetes (17% to 
24%, p < 0.0001). Twenty-one % for deaths related to diabetes (15% to 27%, 
p < 0.0001), 14% for myocardial infarction (8% to 21%, p < 0.0001), and 37% for 
microvascular complications (33% to 41%, p < 0.0001) (Stratton et al., 2000).
Metabolic control is achieved when AIC is less than 7 % (ADA, 2003), 
however, 6.5% or less is recommended by the American Association of Clinical 
Endocrinologists (AACE & the American College of Endocrinology, 2002). FPG level 
is 110 mg/dl or less; post prandal glucose of 140 mg/dl or less. The American Diabetes 
Association's recommendations for glycemic control for people with diabetes are 
illustrated in Table 1.
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Table 1. Glycemic Control for People with Diabetes *
Biochemical Index Nondiabetic Goal
Additional 
Action Suggested
Preprandial glucose (mg/dl)+< 110 80 - 120 <80
> 140
Bedtime glucose (mg/dl)+ <120 100 -140 < 100
> 160
AIC (%) < 6 < 7 >8
* The values shown in this table are by necessity generalized to the entire population of 
individuals with diabetes. Patients with co-morbid diseases, the very young and older adults, and others 
with unusual conditions or circumstances may warrant different treatment goals. These values are for 
nonpregant adults. "Additional action suggested" depends on individual patient circumstances. Such 
actions may include enhanced diabetes self-management education, comanagement with a diabetes team, 
in SMBG, or more frequent contact with the patient. AIC is referenced to a nondiabetic range of 4.0- 
6.0% (mean 5.0%, SD 0.5%). + Measurement of capillary blood glucose.
Reprinted with permission (Appendix F) from the American Diabetes Association (1998). 
Medical Management of Type 2 Diabetes (4th ed.), p.78.
Metabolic Control and Hardiness
Ross (1991) conducted research to determine if the presence of the hardiness 
personality characteristics influences compliance. She used the HRHS (total 40-items 
— 13 items measuring commitment, 13 items measuring challenge, and 14 items 
measuring control) and the Self-Management Compliance Questionnaire to test 50 
hospitalized elderly participants with type 2 diabetes in a large metropolitan hospital in 
the United States. Alpha coefficients for the total HRHS in the study were 0.74. 
Reliabilities for subscales were 0.59 for control, 0.61 for commitment, and 0.49 for 
challenge. The study results revealed a significant correlation between the total HRHS 
(r = - 0.60, p < 0.05) and compliance, although no significant correlations were found 
between the three subscales (control, commitment and challenge) of the HRHS and 
compliance. The study supported the notion that those who comply with their diabetic
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regimen have the characteristics of hardiness. However, this study did not look at AIC 
levels.
To examine the influence of hardiness, self-efficacy, coping style, and 
psychosocial adaptation to illness on the metabolic control of insulin dependent and 
noninsulin dependent adults over the age of 17, Rapley (1990-1991) conducted an 
interview study of a total of 118 volunteers and administered four self-report 
instruments, including the HRHS, Psychosocial Adaptation to Illness Survey, Self- 
Efficacy scale and Ways of Coping Checklist. The reliability of the total HRHS alpha 
was 0.87, but subscales were 0.69 to 0.78. In this study, hardiness was a significant 
predictor of GHb (AIC) levels when adjusted for age, gender and diabetes type. 
Metabolic Control and Self-Efficacy
Discussion of the conceptual issues related to self-efficacy for successful 
management of chronic illnesses like diabetes and rheumatoid arthritis relies on the 
individual's self-care ability to control symptoms and to avoid and/or prevent 
complications. Self-efficacy is central to an individual's view of self and it affects 
behavioral change. Managing chronic illness significantly requires individuals to 
improve confidence in a self-care regimen by increasing self-efficacy. Education is 
absolutely critical to avoid complications in diabetes management. Nurses should 
assess and tailor an education program focused on developing and strengthening an 
individual's sense of self-efficacy because people with strong efficacy beliefs are able to
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withstand failures associated with mastering a complex task and are more likely to 
persist in their efforts with difficult tasks (Rapley & Fruin, 1999).
In a randomized, prospective, cross-over, one year study of 15 adults with type 1 
diabetes to optimize insulin delivery, three intensive management strategies were used. 
The strategies were:
Simplified. This meal plan is based on food exchanges with no self-adjustments 
of insulin for food, exercise and stress.
Qualitative. This meal plan is based on food exchanges with qualitative 
adjustment of insulin.
Quantitative. This meal plan is based on using carbohydrate counting with 
quantitative adjustment of insulin for food and qualitative adjustment for exercise and 
stress. Adjustments of insulin were allowed for all three strategies based on preprandial 
blood glucose and the option of adjusting diet for exercise was allowed. Although there 
were no statistically significant differences in metabolic control, quality of life and self- 
efficacy among the three strategies, there was a clinically significant decrease in AIC 
levels with all strategies compared to baseline (baseline [10.9 + 0.64]; simplified [9.7 +
0.31]; qualitative [9.5 + 0.44] and quantitative [10.2 + 0.43]). There were no 
statistically significant differences in self-efficacy and quality of life between the 
strategies or in relation to time. The authors concluded that a strategy that is not very 
complex, such as "qualitative," and allows for flexibility of self-adjustments of insulin
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may be the strategy of choice for intensive management programs (Kalergis et al.,
2000).
A 12-month study was conducted to examine responses to continuous 
subcutaneous insulin infusion (CSII), known as insulin pump therapy, and multiple 
daily injections (MDI) of insulin in 75 adolescents (aged 12-20) with type 1 diabetes 
and to determine whether either treatment regimen more favorably affected clinical and 
psychosocial outcomes. The study found that the study participants' self-reported 
questionnaires demonstrated that there was improvement in self-efficacy, depression, 
and quality of life in both MDI and CSII treated patients. The average AIC levels were 
analyzed every 4-6 weeks and the results revealed improved metabolic control, initially, 
in both groups. The CSII group's AIC level continued to decrease during the 12-month 
study period (at 6 months AIC = 7.7, at 12 months AIC = 7.5) and the rate of severe 
hypoglycemic events was reduced by almost 50% in this group. The MDI group 
improved metabolic control initially, however, the group had more difficulty sustaining 
improvement for 12 months (at 6 months AlC = 8 .1 ,a tl2  months AIC = 8.3). The 
authors concluded that CSII is an alternative means to lower AIC levels and reduce the 
risk of hypoglycemia without compromising psychosocial outcomes in adolescents with 
type 1 diabetes (Boland, Grey, Oesterle, Fredrickson, & Tamborlane, 1999).
To determine whether a behavioral intervention, coping skills training (CST), 
combined with intensive diabetes management can improve the metabolic control and 
quality of life in adolescents, a randomized study was conducted with a total of 77
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youths aged 12.5 to 20 years. The subjects were assigned into two groups: intensive 
management with coping skills training group or intensive management only group. 
Data were collected at pre-intervention and at 3 and 6 months post-intervention. At the 
conclusion of the study, the subjects who received CST had better metabolic control (F 
= 3.89,p  = .02) and better general self-efficacy (F = 4.54, p = .01). They also reported 
fewer worries about diabetes and less negative impact of diabetes on their quality of life 
(Grey, Boland, Davidson, Yu, & Tamborlane, 1999).
Metabolic Control and Medication Adherence
Nonadherence to medication costs as much as $100 billion annually (Berf,
1993). Moreover, nonadherence with prescribed treatment may be the most serious 
obstacle to effective management of diabetes (Rosenstock, 1985).
A study was conducted to compare sulfonylurea adherence assessment by 
providers, patients' self-report, pill counts, and a medication event monitoring system 
(MEM-S-3 R) device, and to correlate the estimates of metabolic control by provider, 
patient, and laboratory. The study included 47 outpatient veterans with fair to poor 
metabolic control of type 2 diabetes mellitus receiving monthly refills of sulfonylurea in 
vials with a cap containing an electronic medication monitoring microprocessor. 
Outcome measures, including pill counts, monthly fasting plasma glucose, 
glycohemoglobin and a 24-hour diet recall, were obtained at the beginning of the study 
and at 60 days. The providers and patients were asked to assess adherence and 
metabolic control. The results revealed 47% were nonadherent to medication using
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MEMS-i?, 29% using pill counts, 29% using provider assessment, and 31% of patients 
assessed metabolic control differently than laboratory values. Metabolic control was 
not explained by medication adherence by provider, patient, and pill counts. Because 
sulfonylurea adherence and metabolic control both were influenced by numerous 
factors, it was not possible to accurately relate compliance and control (Mason, 
Matsuyama, & Jue, 1995). Adherence to insulin regimen did not correlate significantly 
with glycemic control (Boyer et al., 1996).
Based on the assumption that better regimen adherence produces better 
metabolic control of diabetes, a study investigating the degree of adherence to different 
aspects of the diabetic treatment regimen (insulin injections, glucose testing, diet, and 
exercise), adherence consistency across different regimens, and relationships between 
adherence and metabolic control was conducted. The prospective study included 93 
adult outpatients with insulin dependent diabetes involving two series of home 
interviews at a 6-month interval. The measures of adherence included self-report, 
interview/recall, self-monitoring, and objective indices. The results revealed that the 
degree of adherence was higher for medication taking and glucose monitoring than a 
regimen requiring modification of lifestyle change, e.g., diet and exercise. There was 
no clear relationship between adherence and glycemic control. However, the glycemic 
control measures revealed that older subjects were in better glycemic control than 
younger subjects (AIC = 9.3% vs 11.2%, t = 4.05,;? < 0.001). Duration of diabetes was 
related to several adherence measures, but not to glycemic control indices. Subjects
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with diabetes longer than 10 years reported expending more time in work-related 
activities than subjects with a shorter diabetes history. However, subjects who had 
diabetes 10 years or less reported expending more time in recreational activities, and 
they exercised more days per week. Glucose testing adherence was very stable, but 
adherence to diet and to physical activity were less consistent over time. 
Recommendations for adherence to insulin injection and physical activity were not 
strongly related to adherence to other regimen areas. Males and persons with a longer 
duration of diabetes were less likely to control their eating patterns. "Younger subjects 
with a shorter history of diabetes and males seemed to be more physically active than 
females and persons who have had diabetes for a longer period of time" (Glasgow et al., 
1987, p. 409).
Diabetes regimen adherence is a complex task and performance of any single 
self-care pattern is not strongly related to glycemic control. The authors concluded that 
there is not a straightforward relationship between adherence and control. Regimen 
adherence does not automatically lead to improved metabolic control. And yet, regimen 
adherence should be viewed as one of a variety of factors influencing glycemic control 
(Glasgow, McCaul & Schafer, 1987).
A cross-sectional study was conducted to investigate factors associated with 
adherence to diet and medication in 200 patients with type 2 diabetes mellitus from two 
hospitals in Leon, Mexico. Mean age of the participants in the study was 58.8 years. 
Using multiple regression analysis, the investigators found that adherence to diet was
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associated with years since diagnosis of diabetes indicating that after years of having the 
disease, the participants had less denial and progressively accepted the diagnosis and 
treatment. On the other hand, the higher scores on adherence to medication were 
associated with having an older aged spouse which the authors believed that mature 
partners are more likely to give support to follow medical prescriptions. Adherence to 
medication was lower in patients from families with rigid control than in the group with 
Laissez-faire type of control. Further, rigid control may have an effect on decreased 
adaptation to change toward chronic disease within the family structure and may 
enhance the development of conflict with the authority, increasing the denial of the 
disease (Garay-Sevilla et al., 1995). The authors concluded that adherence to 
medication and diets in patients with type 2 diabetes mellitus are strongly associated 
with social support.
Schectman, Nadkami, & Voss (2002) examined the relationship between 
adherence and diabetes metabolic control in a large indigent population hypothesizing 
that socioeconomic and minority populations have poorer diabetes outcomes and greater 
barriers to adherence. The study included 810 patients with type 2 diabetes who were 
on oral hypoglycemic medications (from the clinic pharmacy) and were receiving 
medical care from a university-based internal medicine clinic serving a low-income 
population in rural central Virginia. Using multiple linear regression, A1C level was 
examined to see whether there was any change in A1C level associated with medication 
adherence, demographics, and clinical characteristics. The findings were:
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1. Adherence to hypoglycemic medication regimens was strongly associated with 
metabolic control in an indigent population. For each 10% increment in drug 
adherence, A1C level decreased by 0.16% at p  < 0.0001. 2. African Americans (versus 
White race) had lower adherence and worse metabolic control; e.g., the mean A1C level 
was 0.29% higher than that of whites at p  = 0.04 when other demographic and clinical 
variables were controlled (Schectman et al., 2002). Consequently, the authors 
emphasized the need for not only facilitating diabetes self-management behaviors of 
low-income populations but also fostering culturally sensitive and appropriate care for 
them.
Hardiness personal constellation has been studied on executives (Kobasa, 1979) 
and on patients with diabetes, but studies specifically looking for the relationship 
between hardiness and metabolic control, in terms of A1C level, on African American 
patients with diabetes are scarce. Rapley (1990-1991) conducted an interview study 
and administered self-report instruments, including the HRHS, to 49 patients with type 
1 diabetes and 48 patients with type 2 diabetes. One of the findings was that "Hardiness 
was a significant predictor of GHb levels when adjusted for age, gender and diabetes 
type." (p. 44), however, the author did not specify the ethnicity of the study subjects. A 
study was conducted using the HRHS to predict compliance in 50 elderly participants 
with diabetes (Ross, 1991). Only 11 subjects were Black.
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Summary
The prevalence of diabetes mellitus is increasing (CDC, National Diabetes Fact 
Sheet, n.d., Retrieved February 23. 2003; Clark, 1998; Burke et al., 1999). Diabetes 
poses a significant public health challenge because it is a serious, complex (Harris,
1998) and costly disease (Clark, 1998). If left uncontrolled, diabetes can cause many 
complications affecting all of an individual's body systems, prompting frequent 
hospitalizations, affecting quality of life and causing premature death. And yet, 
adherence to prescribed hypoglycemic agent is a challenge. Only 50% (across the 
board) of the people who need to take prescribed medications adhere to their regimens 
(Sackett & Snow, 1979; Wright, 1993). Although A1C is not used for screening or 
diagnosing of diabetes, it is a valuable tool (ADA, 2003) because A1C measurement 
improves the sensitivity of screening in high-risk individuals (Perry et ah, 2001) and it 
measures a patient's average glycemia over the preceding 2 to 3 months (ADA, 2003). 
As mentioned in the previous study, A1C level is associated with medication adherence. 
Adherence to hypoglycemic medication regimens was strongly associated with 
metabolic control in an indigent population. For each 10% increment in drug 
adherence, A1C level decreased by 0.16% at p  <0.0001 (Schectman et al., 2002).
This study is different from other studies because this study was focused on 
behavioral manifestations that could contribute toward adherence, thereby improving 
metabolic control. Hence, self-reported behavioral measures were taken using PMAS, 
HRHS, and LTMBSES, then the most recent A1C levels were reviewed for the degree
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of metabolic control. To measure the degrees of diabetes medication adherence, other 
studies relied on self-reported pill counts and a medication event monitoring system 
(MEM-S-3 R) device (Mason et al., 1995); self-reported log for glucose monitoring and 
insulin injections (Glasgow et al, 1987); and calculation using pharmacy prescription 
refill data (Schectman et al., 2002), then either monitoring A1C levels or reviewing the 
existing A1C laboratory values. Although controversial, adherence to hypoglycemic 
medication seems positively related to metabolic outcome. Thus, examining behavioral 
dispositions to determine whether they contribute to metabolic control may generate 
answers and implications for future research.
Hypotheses o f the Study
Null Hypotheses
Hypothesis 1. There is no relationship of metabolic control to hardiness, self- 
efficacy, and hypoglycemic medication adherence.
Hypothesis 2. There is no relationship of metabolic control to cofactors (age, 
education, race, chronic illness, diabetes medications and duration of diabetes). 
Operational Hypothesis
There are positive relationships among metabolic control with hardiness, self- 
efficacy, hypoglycemic medication adherence, and the cofactors (age, education, race, 
chronic illness, diabetes medications and duration of diabetes).
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Chapter III: Methodology
Research Design
This study was a nonexperimental, cross-sectional descriptive-correlational 
design. Three instruments were used for data collection. This design was chosen 
because the purpose of the study was to identify relationships rather than to infer cause- 
and-effect among variables.
Population
The target population for this study was adults with diagnosed diabetes mellitus 
who were undergoing treatments with either oral or insulin hypoglycemic agents.
Sampling Strategy
Sample Selection and Setting
After permission was obtained from the Institutional Review Board (IRB 
permission #2778, Appendix G) to conduct a study involving human subjects, 242 
patients with type 1 or type 2 diabetes from the Diabetes and Primary Care Clinics at 
Virginia Commonwealth University Health System were recruited. The recruitment 
strategies included: (a) discussing the research project with the medical care providers 
and obtaining their help in identifying the potential participants, (b) showing the letter 
of introduction (Appendix H) to the potential participants at the clinic in order to recruit
41
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them, and (c) asking patients while they were being seen at the Diabetes and Primary 
Care Clinics if  they would be willing to participate in the study.
Selection criteria included being adults at least 18 years of age who were 
currently treated with hypoglycemic medication(s) for diabetes; being capable of 
providing self-care; and being able to understand, speak, and write English. Potential 
subjects were screened for selection criteria prior to consent and enrollment.
Every attempt was made to insure that this study included a representative 
sample of adults of all available races and of both genders. However, the overriding 
consideration in assessing a sample in a quantitative study is its representativeness — 
the sample behaves like or has characteristics similar to the population. "Unfortunately, 
there is no method for ensuring absolutely that a sample is representative without 
obtaining the information from the entire population" (Polit & Hungler, 1999, p. 279). 
Once a potential study subject was identified, the co-investigator or a facilitator 
explained the purpose of the study, answered questions, and obtained consent 
(Appendix I) from the potential subject. A study facilitator was hired to assist the co­
investigator with data collection. The study facilitator was trained before data 
collection began. When the study subjects had any questions during the data collection, 
the co-investigator or a facilitator answered questions.
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Sample Size Determination by Power Analysis
In using multiple regression, the sample size should be large enough to
support the data analysis and to decrease the risk of Type II errors. Power
analysis was done using the following formula to obtain estimated effect size
(Y):
0.13 0.13
Y 2 0.15
1 -R 1-0.13 0.87
Then, determined N, the sample size, using 
N =  L + k + 1  (Polit, 1996,p. 285).
Y
15.65
N = + 9 + 1 = 114
0.15
R2 = .13 (moderate effect, Cohen, 1988)
L = tabled value (15.65) for a specified a  = 0.05 and a power of 0.80 (Polit,
1996, p. 286).
y  = estimated effect size (Medium effect size, 0.15, Cohen, 1988).
K = number of predictor variables (Polit, 1996). There are nine predictor 
(hardiness, self-efficacy, perceived medication adherence) and 
cofactor variables (age, education, race, co-morbid chronic illness, 
diabetes medication, duration of diabetes).
A medium effect size of 0.15 was selected because of the assumption that a 
higher score on the Health-Related Hardiness, Long-Term Medication Behavior Self- 
Efficacy, and Perceived Medication Adherence scales would have a medium sized effect 
on the outcome (A1C).
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Considering dropouts, missing data, and inappropriate answers, 242 subjects were 
recruited for the successful completion of the study.
Human Subjects
Permission to conduct the research was obtained from the IRB, Virginia 
Commonwealth University. The patient consent form was used in recruitment of 
subjects. All completed consent forms were stored in a locked cabinet accessible only 
to the co-investigator.
Procedure
Research participants who were diagnosed with diabetes mellitus and were taking 
hypoglycemic medication(s) were recruited from the Diabetes and Primary Care Clinics 
at Virginia Commonwealth University Health System (VCUHS). Only those meeting the 
selection criteria were enrolled. After obtaining consent to participate in the study and 
permission to check their latest laboratory test of A 1C, data collection occurred at the 
time of recruitment. Data were collected from the subjects individually in a private 
setting. Health-Related Hardiness, Long-Term Medication Behavior Self-Efficacy, and 
Perceived Medication Adherence Scales were administered at the beginning of the study. 
Additional data obtained were medical record number, A1C laboratory value, blood 
pressure, height, weight, gender, age, race, education, marital status, religion, type of 
diabetes, duration of the diabetes, diabetes medication regimen, chronic illness, and 
information about their health care provider and communication patterns (Appendix A).
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Operational Definitions
Diabetes Control
Diabetes control was expressed in terms of metabolic control, which was 
measured by A1C (nondiabetic range of 4.0-6.0%, American Diabetes Association, 
1998).
Hardiness Measurement
Hardiness was measured as a total score of the Health-Related Hardiness Scale, 
which included 3 subscales (control, commitment, and challenge). The total score (34 to 
204) was the hardiness predictor variable.
Self-Efficacy Measurement
Self-efficacy was measured by the Long-Term Medication Behavior Self-Efficacy 
Scale, which included 3 subscales (personal attributes, environmental factors and task- 
related and behavior factors). The total score (27 to 135) was the self-efficacy predictor 
variable.
Perceived Medication Adherence Measurement
Medication adherence was measured by the Perceived Medication Adherence 
Scale, which included 3 subscales (self-care, self-efficacy, and decision-making). The 
total score (18 to 90) was the perceived medication adherence predictor variable.
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Demographic Variables
Demographic cofactors included in this study were age, education and race. 
Education was coded as number of years of education. Race was dummy coded as 
1 = African American and 0 = other.
Disease Situation Variables
Disease situation cofactors were comorbid chronic illness, diabetes medications 
prescribed and duration of diabetes. Duration of diabetes was expressed in years. 
Duration of diabetes is a predictor variable.
Instruments
Instruments for the study were the Health-Related Hardiness Scale (Appendix J. 
Permission to use HRHS), the Long-Term Medication Behavior Self-Efficacy Scale 
(Appendix K. Permission to Use LTMBSES) and the Perceived Medication Adherence 
Scale. The instruments are described in Appendix L.
Health-Related Hardiness Scale
The compiled Hardiness Scales rather than a single scale were used to test 
hardiness personalities of public utility male executives in middle to upper levels 
(Kobasa, 1979). Lambert and Lambert (1999) contend that because not all of the 
studies measuring hardiness have used the same instrument, it is difficult to generalize 
findings. It does not seem appropriate to use the same scales to test persons with 
chronic illness, such as persons with diabetes, who require daily management decisions,
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skills, and monitoring as those who are well. Thus, the HRHS by Pollock (1984b; 
Pollock & Duffy, 1990) was developed. This scale is more appropriate for this study.
The HRHS was developed by Pollock (1990) to measure the hardiness construct 
in health-related research. The HRHS, which measures the effect of hardiness 
personality on adaptation to chronic illness, was developed following her in-depth 
evaluation of the concept of stress and adaptation as the stress response. Since its 
inception, the instrument has been used in a variety of health-related and health 
promotion research studies with adults (Pollock, 1999). The current version contains 34 
items on a six-point Likert-type scale ranging from 1 (strongly disagree) to 6 (strongly 
agree) (Pollock, 1990). Scores for the total HRHS range from 34 to 204 with high 
scores indicating presence of hardiness (Pollock, 1993). Scoring for the negatively 
worded items need to be reversed. Depending on the purpose of the investigation, the 
scale can be used to measure the unitary construct of health-related hardiness and/or the 
two dimensions of commitment/challenge (20 items) or control (14 items).
Results of a principal component analysis with chronically ill subjects (N=389) 
supported these two dimensions. The first factor (20 items) encompassed the 
dimensions of commitment and challenge, while the second factor (14 items) accounted 
for the control dimension. The two factors explained 32.1% of the initially extracted 
common variance. The total 34-item HRHS had a standardized alpha coefficient of .91, 
demonstrating high internal consistency. Cronbach's alphas were .87 for both the 20- 
item commitment/challenge subscale and the 14-item control scale.
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Commitment and challenge items loading together suggested that they were 
more closely related and not discrete dimensions in a health-specific context. In other 
words, commitment to adjusting to a health stressor such as chronic illness is also the 
challenge. The HRHS has been used internationally. It has been translated into seven 
languages, and has been used in Africa, Australia, Korea, and Taiwan (Pollock, 1999).
From the refinement process of the scale development, Pollock & Duffy (1990) 
concluded that the HRHS has three main advantages over Kobasa's hardiness measure 
for health-related research. The advantages are: "health specificity, measurement of 
the presence of the factors (commitment/challenge and control) rather than the absence 
to determine hardiness and the easy scoring method" (Pollock & Duffy, 1990, p. 222). 
In other words, although the concept of the HRHS development was based on Kobasa's 
hardiness, the scale construct differs from Kobasa's (1979) in three areas. The 
differences are: (a) the use of health-specific definitions for measuring the concepts of 
control, commitment, and challenge; (b) the measurement of the presence, rather than 
absence, of the three concepts to determine hardiness; and (c) the introduction of the 
concept of health stressor to facilitate health-related research.
Using the adaptation to chronic illness model (Pollock, 1984a) as the theoretical 
framework for integrating the major variables of chronicity, stress, hardiness, and 
physiological and psychosocial adaptation, Pollock (1986) conducted a research study 
with 60 (N = 20 in each group) adults with diabetes mellitus, essential hypertension, or 
rheumatoid arthritis for at least one year. Pollock tested three hypotheses:
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Hypothesis 1. Among persons with rheumatoid arthritis, those who have the 
hardiness characteristic will exhibit more adaptive behavior.
Hypothesis 2. Among persons with insulin-dependent diabetes mellitus, those 
who have the hardiness characteristic will exhibit more adaptive behavior.
Hypothesis 3. Among persons with hypertension, those who have the hardiness 
characteristic will exhibit more adaptive behavior (p. 91).
Pollock (1986) used the HRHS to measure hardiness and physiologic adaptation 
instrument for each diagnostic group. The HRHS contained 48 items on a 6-point 
Likert scale with 15 items measuring commitment, 15 items measuring challenge, and 
18 items measuring control. Reliabilities for the total HRHS (Cronbach's alpha 0.81), 
and for subscales (alpha coefficients 0.84 for control, 0.78 for commitment, and 0.82 
for challenge) indicated good internal consistency. Findings supported hypothesis 2, 
that physiological and psychosocial adaptations were significantly related for the 
diabetic group, but not in the arthritic or hypertensive groups (Pollock, 1986).
Pollock (1989b) studied 30 adults with type 1 diabetes mellitus, ages ranging 
from 21 to 55, to investigate whether or not the presence of hardiness was related to 
physiological adaptation to chronic illness. Further, she was interested in knowing if the 
presence of the hardiness characteristic was related to better physiological adaptation, 
although Pollock did not present findings on physiological adaptation. "Hardiness also 
was related to how one perceives the situation and what one does about the situation" (p. 
273).
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Long-Term Medication Behavior Self-Efficacy Scale
The Long-Term Medication Behavior Self-Efficacy Scale is a 27-item scale 
(revised version) on a five-point Likert-type scale that measures the patient's confidence 
level of self-efficacy from very little (1) to quite a lot (5). The self-efficacy scores range 
from 1 to 5, with higher scores indicating higher levels of self-efficacy. Self-efficacy is 
calculated by summing the scores of all items, then dividing by 27. Because the scale 
was developed as part of a research project in transplant recipients, the item numbers 8, 
9, and 14 are related to side effects of immunosuppressive medication. Per 
recommendation of the author (personal communication, July 16,2000), the items are 
substituted with questions related to hypoglycemic medication side effects. The 
Cronbach's alpha for the scale is 0.88, reflecting good reliability (De Geest et al., 1998). 
Validity of the scale has been established based on results of 1042 subjects who were 
included in several transplant compliance research projects and other studies in chronic 
illness patient populations worldwide.
This scale was used in two separate studies. The first study included a sample of 
150 renal transplant recipients (De Geest et al., 1995) and the second study included a 
sample of 101 heart transplant recipients (De Geest et al., 1998). Self-efficacy was a 
determinant of medication compliance behavior in both studies.
The scale, related to medication behavior, was developed by De Geest et al. 
(1994) following the conduct of a qualitative study using a phenomenological method of 
analysis. The study was focused on exploring patient perception, experiences, and
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practices associated with long-term medication behaviors. In-depth interviews were 
conducted on 14 patients with lifelong dependency on medicine. The themes were 
identified based on Bandura's conceptualization of three dimensions of self-efficacy. 
Dimensions of personal attributes include the themes of emotional distress, confidence in 
the physician, perceived health status, and normalcy. The dimensions of the 
environmental factors identified are the themes of routine, distraction, social support and 
cost of medication. The third dimension of self-efficacy, task-related and behavioral 
factors, was composed of the themes of side effects, drug delivery system, medication 
aids, medication schedule, and knowledge.
Perceived Medication Adherence Scale
The current Perceived Medication Adherence Scale (PMAS) is an 18-item 
instrument with a Likert scale (Allison, 2000) with a format ranging from 5 (Strongly 
agree) to 1 (Strongly disagree) for the positive response items. The scale was refined 
from 19 items to 18 items. The negative response items (83 and 84) were recorded 
ranging from 1 (strongly agree) and 5 (strongly disagree). Each item in the scale is a 
short question reflecting medication adherence. The possible range of scores for the 
current scale is 18 to 90 with a high score indicating the affinity to adhere to prescribed 
medication(s). There are three subscales in the instrument; they are self-care, self- 
efficacy, and decision making. All three subscales contribute to the performance of 
medication adherence. The scale was developed following a literature review, which 
identified the need for such an instrument to measure medication adherence globally.
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The 19-item scale was administered to 200 participants aged 18 to 61 years. A 
total of 152 females (78%) and 48 males (24%) completed the instrument. The subjects' 
willingness to participate and their completion of the instrument were considered as an 
indication of their consent.
Eighty-two percent (n = 164) of the participants were White, non-Hispanic; 8.5% 
were African Americans (n = 17); 4.0% (n -  8) were Asians; 2% (n = 4) were Hispanic; 
and the rest of the participants (3.5%, n = 7) were of other races. Fifty-four percent 
(n -  108) of the participants were master's degree or above educated and 28 % (n = 56) 
were college graduates; 15.5% (n -  31) had some college education; 2% (n = 4) were 
high school graduates; and 0.5% (n = 1) had some high school education. Sixty-nine 
percent (n = 138) were married and 14.5 % (n = 29) were single; 10.5% (n = 21) were 
either divorced or separated; 3% (n = 6) each were widowed and were in a committed 
relationship; 75.5% (n = 151) had children. Fifty-nine percent (n = 118) reported their 
religion as Protestant and the remainder had other religions. Approximately 63%
(n = 127) were employed as health care professionals and 30% (n = 60) had chronic 
illness. Approximately 89% (n = 177) had physicians as their primary care providers 
and 10 % (n = 20) reported nurse practitioners as their primary care providers.
The participants were recruited from various settings including offices, hospitals, 
conference sites, schools, and churches in Washington, D.C., Virginia, and Tennessee. 
Some of the surveys were completed in the presence of the investigator, and some were 
completed at the participant's home and mailed to the investigator later. The factor
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analysis, utilizing principal component analysis, as the extraction method showed 
extraction of communalities ranging 0.347 to 0.611. "Communality is the sum of 
squared loadings (SSL) for a variable across factors" (Tabachnick & Fidell, 1996, p. 
648). Three factors were extracted using Varimax with Kaiser Normalization as the 
rotation method to increase interpretability were extracted. Each factor signifies a 
subscale — self-care, self-efficacy and decision-making. Factor loadings for the self- 
care subscale were 0.323 to 0.913, for the self-efficacy subscale 0.309 to 0.314, and the 
decision making subscale were -0.539 to 0.749. The negative (-0.539) factor loading 
was for the item that reads, "I decide whether I should take my medications." This item 
is the only negative factor loading which may represent lack of similarity among the 
subscale component matrix. Scree plots also supported the existence of three 
components within the PMAS.
Regression analysis on the three subscales revealed a Mahalanobis distance of 
23.514 which is within the maximum range at n = 195, df = 194 and x2 (between 122.7 
to 168.3). This means that there were no subjects who responded erratically.
Reliability analysis on each of the subscales was performed. For the self-care subscale, 
item-total correlations ranged from 0.51 to 0.85, and the Cronbach's alpha was 0.92.
For the self-efficacy subscale, item-total correlations ranged from -0.0085 (the item that 
reads, "I decide whether I should take my medications.") to 0.46, and the Cronbach's 
alpha was 0.42. During the data cleaning process, the scale was recoded. However, the 
same item consistently showed negative correlations. Therefore, the reliability of the
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self-efficacy subscale was analyzed again, and at this time, the item was omitted to see 
whether the correlations were affected. Item-total correlations for the self-efficacy 
subscale without the item ranged from 0.38 to 0.57, and the Cronbach's alpha was 0.65. 
This is a notable change. For item-total correlations, subscale decision-making, ranged 
from 0.09 to 0.45, and the Cronbach's alpha was 0.46. Two subscales, self-care and 
self-efficacy, met the inter-item correlations criteria, which are between 0.30 to 0.70. 
The subscale, decision-making did not meet the criteria because its lower range was - 
0.0085.
Correlations between subscales to total were between .60 to .70, which meet the 
criteria. Correlations between total PMAS and subscales were — self-care 0.94; self- 
efficacy 0.67; and decision-making 0.51 (p=0.01). This shows the correlations between 
total PMAS and self-care and total PMAS and self-efficacy both met the criteria. 
Although the correlation between the subscale decision-making was less than the 
correlation criteria, Cronbach's alpha for the total scale (19 items) was 0.85. This 
indicates that the total PMAS meets the criteria for a new scale since Cronbach's alpha 
is greater than 0.70. Validity of the Medication Adherence Scale (PMAS) is established 
through literature reviews and by the examination of the items by nurse experts.
Content validity of the MAS was established through literature reviews and 
through item examinations by six expert registered nurses — three nurse practitioners 
and three nursing school faculty who have encountered issues of patient medication 
adherence frequently at their nursing practice sites. The original 31-item instrument
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was reviewed item by item by the experts for item clarification, relevancy, congruence, 
wording, and accuracy. Items that were less clear and irrelevant were deleted during the 
review process. A total of 19 items were retained as the final instrument and was 
administered to the 200 subjects. However, this scale was further refined to an 18 item 
scale. Variable, the total scores of the 18 items, for the Medication Adherence Scale is 
90.
Factor analysis, Pearson's correlations, regression, and reliability analysis were 
performed. The highest loading (0.913) item in factor analysis on the self-care subscale 
is the item that states, "I take my medications by the prescribed method." The highest 
loading (0.805) item on the self-efficacy subscale states, "I know why I take each 
medication."
Construct validity was established by examination of correlations between items, 
total PMAS to subscales, and between subscales. Positive correlations were found. 
Concurrent validity examining correlations with another instrument was not done 
because there is no other scale that measures medication adherence based on similar 
subscales of self-care, self-efficacy and decision-making.
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Reading Difficulty Levels o f the Instruments
Reading difficulty levels were determined based on Fry (1977) and DeVellis 
(1991) methods. See Table 2.
Table 2. Reading Difficulty Levels of HRHS, LTMBSES and PMAS*
Instrument Sentences Words (T: 100) Syllables Grade Level
Health-Related
Hardiness
Scale
24 21 28
8th Grade
25 24 30
26 18 22
27 18 19
28 19(18+1) 27
Average N/A 20 25.2
Instrument Sentences Words (T: 100) Syllables Grade Level
Long-Term 
Medication 
Behavior Self- 
Efficacy Scale
10 10 30
6th to 8th Grade
11 15 27
12 17 28
13 16 26
14 12 20
15 19 34
16 11 (12-1) 21
Average N/A 14.3 26.6
Instrument Sentences Words (T: 100) Syllables Grade Level
Perceived
Medication
Adherence
Scale
6 16 27
6th Grade
7 12 16
8 16 20
9 17 24
10 14 17
11 12 16
12 13 17
Average N/A 14.3 19.6
* Reading levels: 5th-grade with 14 words & 18 syllables; 6th-grade with 15/16 words 
& 20 syllables; and 7th-grade with 18 words and 24 syllables per sentence.
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Data Analysis
The SPSS 10.0 Windows statistical software program (SPSS Inc., 1999) was used 
to analyze data. Data were entered as they were collected and surveys were stored in a 
locked cabinet accessible only to the co-investigator, who conducted the data analysis. 
Data were entered and were checked manually for out of range variables and outliers.
For the analysis of data, multiple regression statistical technique was applied to 
predict the relationships, but not imply causal relationships, among one dependent 
variable, metabolic control, 3 predictor variables (hardiness, self-efficacy and perceived 
medication adherence) and 6 cofactors (age, education, race, co-morbid chronic illness, 
diabetes medications and duration of diabetes). In this regression analysis, continuous 
and dummy coded predictor variables were used because the variables were expressed in 
numbers.
Hierarchical (sequential) regression was used. Cofactors entered the equation in 
an order of age, education and race as the first set and comorbid chronic illness, diabetes 
medications and duration of diabetes as the second set. Then, hierarchical order of the 
predictor variables were entered, total scores of the HRHS as the 3rd set, total scores of 
the LTMBSES as the 4th set and total scores of the PMAS as the 5th and final set 
according to theoretical considerations. This created 5 models. Initial differences in age, 
education, race, duration of diabetes, comorbid chronic illness and diabetes medications 
were held constant. The purpose of this process was to hold constant the demographic 
and disease variations while considering the variables of interest: hardiness, self-efficacy,
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and perceived medication adherence. Regression coefficients, the value of R2, and the 
results of correlation and analysis of variance (ANOVA) were reported. Information on
' j
the changes to R at each step of the analysis and the significance of the changes were 
also presented. The tolerances of predictors were examined to detect multicollinearity. 
Residual scatter-plots were inspected, and assessed to determine whether the assumptions 
for multiple regression were violated.
Limitations
This study used a nonexperimental, cross-sectional descriptive-correlational 
design, therefore, conclusions cannot be drawn about causality between the dependent 
variable and the predictor variables. There was no observation of adherence, thus, the 
findings are limited to self-report.
Social desirability response set bias refers to misrepresentation of personal 
attitudes or traits by providing answers in accordance to the social milieu (Polit & 
Hungler, 1997). The study subjects knew they would be paid $10 upon completion of the 
study as a recruitment incentive. That may have interfered with the subjects' responses 
on the questionnaires because they may have subconsciously selected answers that would 
please the coinvestigator who was at the study site.
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Chapter IV: Results
The results of the study are presented in this chapter in the order of description of 
the sample, demographics, description of the variables, and data transformation. 
Following that, the relationships of the response and the predictor variables are examined 
to determine whether assumptions of the multiple regressions were met by examining 
normality, linearity, multicollinearity, and homoscedasticity. The psychometric 
properties of the scales used for this study are evaluated. The PMAS is examined for 
further refinement and retainment of factor structure and psychometric properties as 
observed in the previous study in Summer, 2000. Finally, hypotheses testing, discussion, 
implications and conclusions will follow.
Descriptive Statistics
Description o f the Sample
A convenience sample of the study subjects was recruited to participate in the 
study from the Primary Care Clinics of the Virginia Commonwealth University Health 
System. The study data were collected from 242 patients from A. D. Williams Primary 
Care Clinics (239 patients) including two patients from the Ambulatory Care (ACC) 
Diabetes Clinic and one patient from the private side of the Primary Care Clinic. Of the 
242 study participants, 27 patients were excluded from the data analysis for the following
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reasons: Eleven patients did not complete the questionnaires, one patient was not on any 
hypoglycemic medication, one patient who completed the questionnaires did not have 
diabetes mellitus, and five patients received their diabetes care from sources other than 
the study sites. One patient was not proficient in English. Eight participants with 
responses that reflected inaccurate readings of the questionnaires were excluded from the 
analysis as well. Thus, data from 215 participants were used for analysis.
Demographics
Demographic data of the 215 adult subjects with diabetes who were taking one or 
more hypoglycemic agents revealed the following: More females, 73.5% (n = 158), than 
males, 26.5% (n = 57), participated in the study. The age of the subjects ranged from 19 
to 81 with a mean of 55.5 years. Eleven (5.1%) subjects, were 60 years of age. Nine 
patients (4.2%) from each age group 46, 58, 63 and 64 years of age. Of the 215 subjects 
in the study, 73.5% (n -  158) were African Americans, 20.5% (n = 44) were White, 2.8% 
(n = 6) Hispanics, 1.4% (n = 3) Asians, 1.4% (n = 3) were identified as other, and .5%
(n = 1) gave an invalid response. Education levels ranged from 4 (n = 6, 2.8%) years to 
21 (n -  1, .5%) years. The majority, 67% (n = 144), of the subjects had 10th to 12th grade 
educations. Marital status data showed that 26% (n = 56) were either divorced or 
separated, 25.6% (n -  56) of the subjects were single, 23.7% (n = 51) were married, and 
21.9% (47) of the subjects were widowed. Almost half (48.8%, n = 105) subjects were 
Protestant, 40.5% (n = 87) reported other religions, 7.4% (n = 16) were Catholic, 1.4%
(n = 3) were Islam, .9% (n -  2) reported no religion, and .5% (n = 1) was Jewish.
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In terms of type of diabetes, 94.4% (n — 203) reported having type 2 diabetes and 
5.6% ( n -  12) marked as having type 1 diabetes. This finding is congruent with the 
national statistics indicating that 5% to 10% of the patients with diabetes having type 1 
diabetes and 90% to 95% have type 2 diabetes (Centers for Disease Control and 
Prevention Diabetes and Public Health Resource, 1998). Duration of diabetes ranged 
from 0.5 month to 42 years; the highest percent (10.2%, n = 22) had diabetes for 10 
years. Fifty-three percent (n = 114) of the subjects were on oral hypoglycemic agents, 
24.7% (n = 53) were on insulin only, and 22.3% (n = 48) were on a combination of 
insulin and oral agents.
The subjects were asked what other chronic illnesses they had besides diabetes.
Of the 215 subjects, only 7% (n = 15) had no other chronic illness. Twenty-six percent 
(n = 56) had hypertension, 19.1% (n = 41) had hypertension and high cholesterol, 12.1% 
(n = 26) had hypertension, heart conditions and high cholesterol. The majority of 
subjects' health care providers were physicians (79.5%, n = 171). Other providers 
reported were nurse practitioners (NP), 12.1% (n = 26); other 2.8% (n = 6); combination 
of physician and NP 3.3% (n = 7); and combination of physician and other licensed 
practitioner, physician and other provider, or NP and other provider 1.5%
(n = 3). The subjects' responses on their providers' calls to check on their medication 
adherence were 48.8% (n = 105) for every 3 months, 18.6% (n = 40) for never, 12.6% (n 
= 27) for every month, 11.2% (n = 24) for rarely, and .5% (n = 1) for weekly. Overall,
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81% (n = 174) of the subjects reported that they receive follow-up calls from their 
providers checking on their medication-taking practices.
The subjects' heights, weights and blood pressures were obtained by chart reviews. 
Height ranged from 51 inches to 75 inches with a mean of 65.7 inches. Their weight 
ranged from 105 pounds to 417.9 pounds with a mean of 211.3 pounds (a median of 207 
pounds). Body mass index (BMI) ranged from 15.5 to 59.6 with a mean of 34.3 kg/m2.
In this study, 16% (n = 35) of the subjects were obese (BMI > 27 kg/m2) and 65% (n = 
140) of the subjects were morbidly obese (BMI > 30 kg/m2). When these subjects were 
counted together, 81 %(n =  175) of the total study participants were either obese or 
morbidly obese. According to the ADA specification, systolic blood pressure (SBP) 
should be under 130 mmHg and diastolic blood pressure (DBP) less than 85 mmHg as a 
goal to achieve for patients with diabetes. In this study, SBP ranged from 82 to 231 with 
a mean of 141 mmHg, and DBP ranged from 53 to 130 with a mean of 77 mmHg. 
Seventy percent (n = 150) of the subjects had SBP >130 mmHg and 21% (n = 45) of the 
subjects had DBP >85 mmHg.
Nearly 38% (n = 81) of the subjects were receiving their diabetes care from the 
A.D. Williams Primary Care Clinic (ADWPCC), West, 36.7% (n = 79) from the 
ADWPCC, Central, and 24.2% (n = 52) were from the ADWPCC, East. Two (.9%) 
patients were from the Ambulatory Care Clinic (ACC) Diabetes Clinic, and one patient 
(.5%) who participated in the study was from the ACC Primary Care Clinic.
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The variables, race and religion, were recoded for better distribution for the 
analysis. Race was recoded as 1= African American and 0 = other. Religion was 
recoded as 1 = Protestant and 0 = other. See Table 3 for Demographic Characteristics of 
the sample (n = 215).
Table 3. Demographic Characteristics of the Sample (n = 215)
Variables Subject Characteristics
Gender Female (n = 158, 73.5%); Male (n = 57, 26.5%)
Age Mean: 55.5; Range: 19 to 81
Race African American (n = 158, 73.5%); White (n = 44, 20.5%); 
Hispanic (n = 6, 2.8%); Asian (n = 3, 1.4%); Other (n = 3, 1.4%); 
Invalid (n = 1, 0.5%)
Education Mean: 11 years, Range: 4 to 21 years
Marital Status Divorced/Separated (n = 56, 26 %); Single (n = 55, 25.6%); 
Married 0  = 51, 23.7%); Widowed (n = 47, 21.9%); 
Missing (n = 6, 2.8%)
Religion Protestant (n = 105, 48.8%); Other (n = 87, 40.5%);
Catholic 0  = 16, 7.4%); Islam (n = 3, 1.4%); None 0  = 2, 0.9%); 
Jewish {n =  \, 0.5%); Invalid {n = \, 0.5%)
Type of Diabetes Type 1 0  = 12, 5.6%); Type 2 0  = 203, 94.4%)
Duration of 
Diabetes
Mean: 9.9 years; Range: 0.04 to 42 years
Diabetes
Medication
Oral 0  = 114, 53%); Insulin only (n = 53, 24.7%); 
Insulin & oral (n = 48, 22.3%)
Chronic Illness 
Beside Diabetes
HTN 0  = 56, 26%); HTN & high cholesterol (n = 41, 19.1%);
HTN, heart condition & high cholesterol O  = 26, 12.1%); None 
0 = 1 5 ,  7.0%); HTN & Heart condition (w = 11, 5.1%);
HTN & other 0  = 11,5.1%); HTN, heart condition, high cholesterol 
& other 0  = 10, 4.7%); High cholesterol (n -  8, 3.7%); HTN, high 
cholesterol & other 0  = 8, 3.7%); heart condition (n = 7, 3.3%); 
heart cond. & high cholesterol (n = 4, 1.9%); HTN, heart condition 
& kidney failure (n = 3, 1.4%); kidney failure O = 1, 0.5%); heart 
condition & other 0  = 1, 0.5%); high cholesterol & other 
0 = 1 ,  0.5%); heart condition, high cholesterol & other 
0  = 1, 0.5%); HTN, high cholesterol kidney failure & other 
0 = 1 ,  0.5%)
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Health Care 
Provider
Physician (n = 171, 79.5%); NP (n -  26, 12.1%); Physican & NP (n 
= 7, 3.3%); other (n = 6, 2.8%); OLP (n = 2, 0.9%); Physician & 
OLP (n = 1, 0.5%); Physician & other (n = 1, 0.5%); NP & other 
(n = 1, 0.5%)
Provider(s) Call Q3months (n = 105, 48.8%); never (n = 40, 18.6%); Qmonth 
(n = 27, 12.6%); rarely (n = 24, 11.2%); Q6months (n = 17, 7.9%); 
N/A (n = 1, 0.5%); weekly (n = 1, 0.5%)
Height (inches) Mean: 65.7; range: 51 to 75 inches
Weight (lbs) Mean: 211.3; range: 105 (A1C: 7.5) to 417.90 (A1C: 6.2); weight 
between 200 to 417.9 pounds (n = 124, 58.8%)
BMI Mean: 34.3; range: 15.5 (A1C: 5.8) to 59.6 (A1C: 6.3)
SBP Mean: 141; range: 82 to 231 mm/Hg
DBP Mean: 77; range: 53 to 130 mm/Hg
Clinic Location ADWPCC West (w = 81, 37.7%); ADWPCC Central
in = 79, 36. 7%); ADWPCC East (n = 52, 24.2%); ACC Diabetes
Clinic {n = 2, 0.9%); ACCPCC (« = 1, 0.5%)
Description o f Variables
The subjects' age ranged from 19 to 81 years of age with a mean of 55.5 (SD
11.46); skewness (asymmetrical distribution) was -.36 and Kurtosis (peakedness of a 
distribution) was .03. The histogram of age distribution appears to be fairly normal, 
although a slight and not obvious skewness to the right was noted. The majority (73.5%, 
n = 158) of the subjects were African Americans. Education levels ranged from 4 (n = 6, 
2.8%) years to 21 (n = 1, .5%) years with a mean of 11 years with skewness of .20 and 
kurtosis of 2.41. Duration of diabetes ranged from .04 to 42 years with a mean of 9.9 
years, skewness of 1.511 and kurtosis of 2.405. The majority, 53% (n = 114), of the 
subjects were on oral agents, 24.7% (n = 53) were on insulin only, and 22.3% (n = 48) 
were on a combination of insulin and oral agents. Only 7% (n = 15) of the subjects had
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no chronic illness other than diabetes. The remaining 93% (n = 200) of the subjects had 
chronic illnesses. Hypertension (26%, n = 56) was the predominant chronic condition, 
and hypertension with the combination of a heart condition and/or high cholesterol 
problems were the next most common chronic conditions that the subjects reported in 
addition to diabetes.
The response variable, A1C (laboratory value), and the predictor variables, 
Hardiness, measured by the HRHS, Self-Efficacy, measured by the LTMBSES, and 
Perceived Medication Adherence, measured by the PMAS were examined to determine 
the distributions of normality. Further, linearity, multicollinearity (interrelatedness of the 
independent variables) and homoscedasticity (distribution variability between response 
and predictor variables) of relationships between the predictor and response variables 
were examined to determine whether assumptions of multiple regression were met. The 
response variable, A1C value, was obtained from the patients' laboratory record by 
accessing the hospital computer system or by reviewing the patients' medical records 
after obtaining the patients' consents (Appendix I). The Primus CLC 385 Glycated 
Hemoglobin Analysis was the test for A1C at the chemistry laboratory of the VCUHS. 
The cofactors, demographics (age, education, race) and disease situation (comorbid 
chronic illness, diabetes medication, and duration of diabetes) were also examined. Thus, 
variable statistics included were age, race, education, duration of diabetes, diabetes 
medications, total HRHS (n = 215), total LTMBSES (n = 215), total PMAS (n = 215), 
and A1C (n = 211).
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The total score of HRHS can range from 34 to 204. In this study, it ranged from 
94 to 185 with a mean of 145, SD 16.81, skewness of -.35 and kurtosis of -.05. A 
histogram of HRHS appears to be normally distributed (Figure 6).
Total HRHS
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Figure 6. Total HRHS with Fit Line
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The score of the total LTMBSES can range from 27 to 135 and in this study 
it ranged from 51 to 135 with a mean of 102.56, SD 18.53, skewness of -.65 and kurtosis 
of -.62. A histogram of LTMBSES shows some kurtosis (Figure 7).
Total LTMBSES
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Figure 7. Total LTMBSES with Fit Line
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
68
The scores of the total PMAS can range from 18 to 90 and in this study it ranged 
from 59 to 90 with a mean of 82, SD 7.40, skewness of -1.00 and kurtosis of .04. A 
histogram of PMAS shows some skewness to the right and minimal kurtosis (Figure 8).
TOTAL PMAS
Mean = 81.6
60.0 65.0 70.0 75.0 80.0 85.0 90.0
62.5 67.5 72.5 77.5 82.5 87.5
Figure 8. Total PMAS with Fit Line
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The response variable, A1C, ranged from 4.8 to 15.7 (Table 4, A1C Distribution) 
with a mean of 7.8%, SD 2.13, skewness of 1.24 and kurtosis of 1.58. See Table 4 for 
Variable Statistics.
Table 4. A1C Distribution
A1C Range Number of Subjects Percent
4.8 to 6.9 88 41.71
7.0 to 8.0 44 20.85
8.1 to 9.0 35 16.59
9.1 to 10.0 16 7.58
10.1 to 11.0 9 4.27
11.0 to 12.0 7 3.32
12.1 to 13.0 4 1.90
13.1 to 14.0 5 2.37
14.1 to 15.0 1 0.47
15.1 to 15.7 2 0.94
Total 211 100%
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The histogram of A1C shows some skewness and kurtosis in distribution. See 
Figure 9.
A1C (%)
Figuire 9. Distribution of A1C with Fit Line
Studentized deleted residuals were used to examine normality because they make 
it easier to spot unusual points. When sample size is much larger than 30, the distribution 
of the studentized deleted residuals should be approximately normal (Norusis, 2000). 
Residuals statistics show that the Mahalanobis distance ranges from 1.63 to 38.41 with a 
mean of 8.96 (SD 6.22). Mahalanobis distance is a measure of the distance of a case 
from the average values of all the independent variables (Norsusis, 2000). For this study, 
Mahalanobis distance was calculated (SPSS Inc., 1999) using the formula, (N-l) 
(leverage) = (215 -1) (0.13) = 27.82. N being the number of case, leverage = 3P/N, P 
being the number of variables which is 9 for this case. The maximum distance of the
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Mahalanobis distance, 38.41, is much higher than expected (27.82). The high 
Mahalanobis distance is because of five subjects (ID 63, 79, 99, 102 and 137) with A1C 
values 15.7, 13.2, 14.6, 15.4, and 13.3, which were detected by the casewise diagnostics. 
These are the multivariate outliers, however, the laboratory values of A1C are each 
subject's physiological measure of metabolic control and cannot be substituted. Thus, the 
high A1C levels should not be eliminated from the data or be transformed in attempt to 
reduce the influence of outliers for the analysis.
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Table 5. Variable Statistics
Age Race Edu Dur/
Diab
(yrs.)
Diab/
Med
Chr/
ill
Total
HRHS
Total
LTMBSES
Total
PMAS
A1C
(mg/dl)
N 215 215 215 215 215 215 215 215 215 211
Mean 55.51 - 10.96 9.88 - - 144.70 102.56 81.64 7.85
SD 11.46 - 2.64 8.83 - - 16.81 18.53 7.40 2.13
Skew-nesss -.36 - .20 1.51 - - -.35 -.65 -1.00 1.24
Kurtosis .03 - 2.41 2.41 - - -.05 -.62 .04 1.58
Range 19-81 - 4 -2 1 .04 -4 - - 94 -1 8 51 - 135 59 -9 0 4.8-15.7
Data Transformation
Data Cleaning
Data were entered manually. Then, the data were reviewed for accuracy and any 
discrepancies compared to the original data were corrected. The negatively worded item 
numbers 15, 16, 17, 21, 22, 23, 25, 27, 32, 34, 35, 37, 38, 46, 54, 55, 60, 83 and 84 were 
recoded. There were 17 missing values - items 17, 23, 30, 40, 52 (3 subjects missed) 54, 
55, 56, 63, 69, 71, 72 (considered as missing value because one subject marked 2 
responses for this item), 78 and 83 (2 subjects missed).
Missing Value Mean Substitutions
In order to avoid loss of subjects and maintain all cases with complete data 
(Munro, 2001), mean substitutions were conducted because "if cases with missing values 
are not randomly distributed through the data, distortions of the sample occur if they are 
deleted" (Tabachnick & Fidell, 1996, p. 63). The missing values were estimated using 
regression and frequency means, and it was found that the estimations from these two
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methods were comparable, mostly higher points from regression means. The rounded 
values of the regression means were substituted for the missing values (Table 6).
Table 6. Regression Mean Values
Varibles Std. Deviation Mean Substitution N
vl7. H-my efforts. 1.82 2.91 3 196
v23. H-eat & exercise. 1.86 3.07 3 196
v30. H-sick-get well. 1.94 4.09 4 196
v40. H-excited-improving. 1.29 5.29 5 196
v52. S-taking meds at work. 1.50 3.84 4 196
v54. S-taking meds cause hungry. 1.29 4.11 4 196
v55. S-taking meds drop BP<50. 1.48 3.41 3 196
v56. S-taking meds when healthy. 1.02 4.40 4 196
v63. S-taking meds angry at friend. 1.46 3.80 4 196
v69. S-taking meds sick stomach. 1.42 3.60 4 196
v71. S-taking meds at party. 1.63 4.48 4 196
v72. S-taking meds long walk. 1.59 3.37 3 196
v78. M-I complete rx as directed. 3.63 4.99 5 196
v83. I skip my meds when busy. 1.41 2.10 2 196
Normality, Linearity, Multicollinearity, and Homoscedasticity 
A test of assumptions of normality, linearity, multicollinearity, and 
homoscedasticity can be assessed by examination of residuals scatterplots between 
predicted dependent variable scores and errors of prediction. When the residuals 
(differences between obtained and predicted dependent variable scores) are normally 
distributed about the predicted dependent variable scores, residuals have a straight line 
relationship with the predicted dependent scores (Tabachnick & Fidell, 1996). 
Scatterplot of studentized deleted residuals in the plots are preferred by many 
researchers because with use of a valid application of the model to compute the
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residuals, they have a mean of 0 and a variance of 1. Further, if the errors are normally 
distributed, and the form of the model is correct, then about 95% of the residuals should 
fall between -2 and +2. When the residuals are from a normal distribution, the plotted 
values fall roughly along the line (SPSS Inc., 1999). For this study, looking at the plots 
of the normal probability plots (Figure 10) and regression studentized deleted residual 
with fit line (Figure 11) of the response variable, A 1C, normality and linearity are 
evident.
Normal P-P Plot of Regression Standardized Residual 
Dependent Variable: A1C (%)
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Figure 10. Normal P-P Plot of Regression Standardized Residual of A1C with Fit Line 
Cum Prob = Cumulative Probability.
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Scatterplot 
Dependent Variable: A1C (%)
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Figure 11. Regression Studentized Deleted Residual with Fit Line of A1C
Multicollinearity (interrelatedness of independent variables) can be detected by 
examining the tolerance of predictors (Polit, 1996). A tolerance (1 - R2) of 0 
( 1 - 1 = 0 )  indicates perfect collinearity (Munro, 2001). Values for tolerance for this 
study are .97 to 1.00 for model 1; .90 to .97 for models 2; .90 to .96 for model 3; .88 to 
.96 for model 4 and .70 to .96 for model 5. Therefore, multicollinearity is not a 
problem for this study, indicating that there is no interrelatedness between independent 
variables. When the assumption of multivariate normality is met, the relationships 
between variables are homoscedastic (Tabachnick & Fidell, 1996). Thus, the 
relationships among variables for this study are homoscedastic (for each value of X, 
the variability of Y scores is approximately the same, Polit, 1996).
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Psychometric Analysis o f the Study Instruments 
Psychometric analysis of the three study scales, Health-Related Hardiness Scale 
(HRHS), Long-Term Medication Behavior Self-Efficacy Scale (LTMBSES) and 
Perceived Medication Adherence Scale (PMAS), were performed to determine their 
reliabilities and validities.
Health-Related Hardiness Scale (HRHS)
HRHS measures the hardiness construct that is used to measure the unitary 
construct of health-related hardiness by using the total score for this study in 215 adults 
with diabetes mellitus. The scale contains 34-items on a six-point Likert-type scale, 
"strongly disagree to strongly agree", with high scores indicating presence of hardiness. 
The possible total score of the scale ranges from 34 to 204. For this study the score 
ranged from 94 to 185. Item mean is 4.26, ranging from 2.04 to 5.47, with a variance of 
.88 .
The reliability coefficient, Cronbach's alpha, is .67 and standardized item alpha is 
.71 (Table 7).
Table 7. Reliability Scale of HRHS
34 Item (HRHS) 
Means
Mean Min. Max. Range Variance Alpha Stand.
Alpha
Values 4.26 2.04 5.47 3.44 .88 .67 .71
The author of the HRHS developed an instrument that can be used to measure the 
unitary construct of health-related hardiness and/or the two dimensions of
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commitment/challenge. Factor analysis using varimax rotation was performed. The 
principal component analysis extraction method of scree plot of HRHS shows two factors 
(Figure 12) present within the scale with initial Eigenvalues (variances of the 
components) (SPSS, Inc., 1999); the total amount of variance explained by a factor 
(Munro, 2001) of 6.01 and 4.05 accounting for variance of 29.60 %.
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Figure 12. Scree Plot of HRHS
Long-Term Medication Behavior Self-Efficacy Scale (LTMBSES)
LTMBSES measures self-efficacy as a determinant of medication compliance 
behavior. This scale contains 27-items on a five-point Likert-type scale, "very little to 
quite a lot", with higher scores indicating higher levels of self-efficacy. The possible 
total score of the scale ranges from 27 to 135. For this study, the score ranged from 51
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to 135 with a mean of 102.56 (SD 18.53) based on N = 215. The item mean is 3.80, 
ranged from 1.95 to 4.51 with a variance of .43.
The reliability coefficient, Cronbach's alpha = .90 and the standardized item 
alpha = .91 are reported. See Table 8.
Table 8. Reliability Scale of LTMBSES
27 Item
(LTMBSES)
Means
Mean Min. Max. Range Variance Alpha Stand.
Alpha
Values 3.80 1.95 4.51 2.56 .43 .90 .91
Factor analysis using varimax rotation was performed. Principal component 
analysis extraction method of the scree plot shows two factors (Figure 13) present 
within the scale with initial Eigenvalues of 11.73, and 2.24 accounting for variance of 
51.70%.
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Scree Plot OF LTMBSES
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Figure 13. Scree Plot of LTMBSES 
Perceived Medication Adherence Scale (PMAS)
PMAS measures perceived medication adherence. The scale contains 18 items 
on a five-point Likert-type scale, "strongly disagree to strongly agree", with higher 
scores indicating higher levels of perceived medication adherence. The total possible 
score of the scale ranges from 18 to 90. For this study, the score ranged from 59 to 90 
with a mean of 81.64 (SD 7.40) based on n = 215. The item mean was 4.54, ranging 
from 3.36 to 4.77 with a variance of .13. The reliability coefficient was .83 (Cronbach's 
alpha) and the standardized item alpha = .90 (Table 9).
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Table 9. Reliability Scale of PMAS
18 Item (PMAS) Mean Min. Max. Range Variance Alpha Stand.
Alpha
Values 4.54 3.36 4.77 1.41 .13 .83 .90
Factor analysis using varimax rotation was performed. The principal component 
analysis extraction method of the scree plot shows one factor present {Figure 14) within 
the scale with initial Eigenvalues of 7.39 and 1.58, accounting for variance of 49.82%.
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Figure 14. Scree Plot of PMAS
The PMAS scale used for this study was examined for further refinement, and 
for retainment of factor structure and psychometric properties as observed in the 
previous study in Summer, 2000 (Medication Adherence Scale). Correlations of PMAS 
with other variables (HRHS, LTMBSES, and A1C) revealed .26 with HRHS (p = .000), 
.50 with LTMBSES (p = 000), and -.09 with A1C (p = .193). This means that the
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correlations of the PMAS with other predictor variables is substantial for LTMBSES 
because the correlations between the variables are between .30 and .70 (Munro, 2001), 
a = .01, p = .00, but only with one scale, LTMBSES.
Principal component analysis extraction method of communalities showed that 
the highest loading (.84) in the scale was item #80, "I take my medications as 
prescribed." The factor loadings ranged from .44 to .84. A two-tailed Pearson's 
correlation was performed on the 18-item PMAS scale (N=215). Of the 318 inter-item 
correlations, 216 were significant atp  = 0.01 level, 16 were significant at p  = 0.05 level, 
and 86 were not significant. The Pearson's correlations ranged from .01 to .76. See 
Table 10. Reliability of the total PMAS was .83, and standardized item a = .90.
Table 10. Comparison of PMAS and MAS
Scale N Item Communalitie
s
Alpha IIC* Mean SD
PMAS, 2003 215 18 .44 to .84 .83 .01 to .76 81.64 7.40
MAS, 2000 200 19 .35 to .61 .85 -.01 to .86 80.00 8.18
* IIC: Inter-Item Correlation
Hypotheses Testing
Null Hypothesis 1
"There is no relationship of metabolic control to hardiness, self-efficacy and 
hypoglycemic medication adherence."
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To examine the relationships and predictability of A1C (metabolic control) 
between A1C and total scores of HRHS, LTMBSES and PMAS, Pearson's correlations 
(significance, 2-tailed), regression, and ANOVA were performed. "Beta reflects the 
weight associated with standardized scores (z-scores) on the variables. It is a partial 
correlation coefficient, a measure of the relationship between an independent and a 
dependent variable with the influence of the other independent variables held constant" 
(Munro, 2001, p. 256). HRHS had a correlation of .10 with A1C level, which is not 
statistically significant (p = .14), moreover, when the other predictor variables are 
accounted for, the partial correlation coefficient, Beta, between A1C level and HRHS is 
only .12 (p = .09), which also is not significant. LTMBSES had a correlation of -.07 
with A1C level, which is not statistically significant (p = .28). Further, when the other 
predictor variables are accounted for, the partial correlation, Beta, between A1C level 
and LTMBSES is only -.01 (p = .95), which also is not significant. PMAS had a 
correlation of -.09, which is not statistically significant (p = .19), moreover, when the 
other predictor variables are accounted for, the partial correlation, Beta, between A1C 
level and PMAS is -.11, which also is not significant (p = .15). See Table 11 for 
correlations of the variables.
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Table 11. Correlations of HRHS, LTMBSES, PMAS and A1C
Correlations
Total HRHS
Total
LTMBSES Total PMAS A1C (%)
lota I HKHS Kearson uorreiation 1.000 .258^ .251^ .102
Sig. (2-tailed) .000 .000 .140
N 215 215 215 211
Total LTMBSES Pearson Correlation .258** 1.000 .498** -.074
Sig. (2-tailed) .000 .000 .283
N 215 215 215 211
Total PMAS Pearson Correlation .261** .498** 1.000 -.090
Sig. (2-tailed) .000 .000 .193
N 215 215 215 211
A 'l’C (%) Pearson Correlation .102 -.074 -.090 1.000
Sig. (2-tailed) .140 .283 .193
N 211 211 211 211
**• Correlation is significant at the 0.01 level (2-tailed).
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For this analysis, the regression of A1C (metabolic control) on three predictor 
variables (total scores of HRHS, LTMBSES, and PMAS) accounted for 13% of the 
variance (See Table 12). This finding was significant at the .001 level (see Table 13 
ANOVA Table.
Table 12. Model Summary
Model Summary*
Model R
R
Square
Adjusted 
R Square
Std. Error of 
the Estimate
Change Statistics
R
Square
Change
F
Change df1 df2
Sig. F 
Change
i .275a .075 .062 2.055 ,67b 5.657 3 207 .001
2 .329b .108 .082 2.044 .032 2.469 3 204 .063
3 ,340c .115 .085 2.041 .007 1.669 1 203 .198
4 .344d .118 .083 2.043 .003 .651 1 202 .421
5 .357e .127 .088 2.037 .009 2.093 1 201 .149
a- Predictors: (Constant), edu, race, age
b- Predictors: (Constant), edu, race, age, diabe/med, dura/diabe, chronic/ill
c- Predictors: (Constant), edu, race, age, diabe/med, dura/diabe, chronic/ill, Total HRHS
Predictors: (Constant), edu, race, age, diabe/med, dura/diabe, chronic/ill, Total HRHS, Total
LTMBSES
e- Predictors: (Constant), edu, race, age, diabe/med, dura/diabe, chronic/ill, Total HRHS, Total 
LTMBSES, Total PMAS
Dependent Variable: A1C (mg/dl)
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Table 13. ANOVA Table Showing Significance of A1C Outcome
ANOVA
Model
Sum of 
Squares df Mean Square F Sig.
1 Regression 72.442 3 24.147 5.657 .001a
Residual 883.661 207 4.269
Total 956.102 210
2 Regression 103.407 6 17.234 4.123 o o a
Residual 852.695 204 4.180
Total 956.102 210
3 Regression 110.359 7 15.766 3.784
oOo
Residual 845.743 203 4.166
Total 956.102 210
4 Regression 113.076 8 14.134 3.387 .001°
Residual 843.027 202 4.173
Total 956.102 210
5 Regression 121.765 9 13.529 3.259 ,001e
Residual 834.337 201 4.151
Total 956.102 210
a  Predictors: (Constant), edu, race, age
b- Predictors: (Constant), edu, race, age, diabe/med, dura/diabe, chronic/ill
c- Predictors: (Constant), edu, race, age, diabe/med, dura/diabe, chronic/ill, Total 
HRHS
d- Predictors: (Constant), edu, race, age, diabe/med, dura/diabe, chronic/ill, Total 
HRHS, Total LTMBSES
e- Predictors: (Constant), edu, race, age, diabe/med, dura/diabe, chronic/ill, Total 
HRHS, Total LTMBSES, Total PMAS
Dependent Variable: A1C (mg/dl)
Hardiness was not significantly related to metabolic control. There was a negative 
relationship between self-efficacy and metabolic control, indicating that adults with 
diabetes mellitus having high self-efficacy will have better metabolic control but it was 
statistically not significant. There was a negative relationship between perceived 
medication adherence and metabolic control, indicating that adults with diabetes mellitus
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having higher perceived medication adherence will have better metabolic control but it 
was statistically not significant.
The prediction equation for this analysis by using 6-weights is (Table 14): 
Predicted level on A1C (metabolic control) = 9.20 + 1.52E-02 (hardiness) - 5.33E-04 
(self-efficacy) - 3.25E-02 (perceived medication adherence). To calculate the predicted 
A1C, the mean values of hardiness, self-efficacy and perceived medication adherence 
were plugged in, yielding: A1C (predicted) = 9.20 + 0.0152 (144.79) - 0.000533 
(102.56) - 0.0325 (81.64) = 9.20 + 2.20 - 0.055 - 2.65 = 8.70 (%). The actual mean A1C 
is 7.85.
Table 14 Coefficients
Model 5 
Variables
U.std. Coeff U.std.Coef Std.Coef
t Sig.6-weight Std. Error Beta
Constant 9.20 2.02 4.56 .00
Age -4.720E-02 .01 -.25 -3.66 .00
Race .41 .34 .08 1.20 .23
Edu 4.303E-02 .06 .05 .78 .44
Dura/diab 2.422E-02 .02 .10 1.46 .15
Diab/med .43 .21 .14 2.03 .04
Chronic/ill -8.301E-04 .00 -.11 -1.53 .13
Total HRHS 1.515E-02 .01 .12 1.69 .09
T.LTMBSES -5.328E-04 .01 -.01 -.06 .95
Total PMAS -3.246E-02 .02 -.11 -1.45 .15
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These results failed to reject hypothesis 1 that there is no relationship of 
metabolic control to hardiness, self-efficacy and perceived medication adherence.
Null Hypothesis 2
"There is no relationship of metabolic control to cofactors (age, education, race, 
chronic illness, diabetes medications and duration of diabetes)."
To examine the relationships and predictability of metabolic control between 
A1C and cofactor variables (age, race, education, duration of diabetes, diabetes 
medications, and chronic illnesses other than diabetes), Pearson's correlations 
(significance, 2-tailed), regression and ANOVA were performed. Age had a correlation 
of -.25 with A1C level, which is significant (p = .00). When the other predictor 
variables are accounted for, the partial correlation (Beta) between A1C level and age is 
-.25 {p = .00), which also is significant. Education level had a correlation of .11 with 
A1C level, which is not significant (p = .11). When the other predictor variables are 
accounted for, the partial correlation (Beta) between A1C level and educational level is 
.05, which also is not significant (p = .44). Race had a correlation of .09 with A1C 
level, which is not significant (p = .20). When the other predictor variables are 
accounted for, the partial correlation (Beta) between A1C level and race is .08, which 
also is not significant (p = .20). Duration of diabetes had a correlation of .03 with A1C 
level, which is not significant (p = .63). When the other predictor variables are 
accounted for, the partial correlation (Beta) between A1C level and duration of diabetes 
is .10, which also is not significant
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(p = .15). Diabetes medication had a correlation of .10 with A1C level, which is not 
significant (p = .17), but when the other predictor variables are accounted for, the partial 
correlation (Beta) between A1C level and diabetes medication is .14, which is 
significant (p = .04). Chronic illness other than diabetes had a correlation of -.12 with 
A1C, which is not significant (p = .09). When the other predictor variables are 
accounted for, the partial correlation (Beta) between A1C level and chronic illness is - 
.11, which also is not significant (p = .13).
For this analysis, the regression of A1C (metabolic control) on six cofactor, 
predictor variables (age, educational level, race, duration of diabetes, diabetes 
medications and chronic illness) accounted for 13% of the variance and was significant 
at the .001 level (ANOVA table). There was a negative relationship (-.25,p  = .00) 
between age and A1C, indicating that the older the adult with diabetes, the better his/her 
metabolic control. Educational level was not significantly related to metabolic control. 
Race, duration of diabetes, diabetes medication, and chronic illness were not 
significantly related to metabolic control.
The prediction equation based on this analysis by using beta weights (.B) is: 
Predicted level on A1C (metabolic control) = 9.20 - 4.72E-02 (age) + 4.30E-02 
(education) + .41 (race) + 2.42E-02 (duration of diabetes) + .43 (diabetes medication) - 
8.30E-04 (chronic illness).
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These results failed to reject the null hypothesis that there is no relationship of 
metabolic control to cofactors (education, race, chronic illness, diabetes medications 
and duration of diabetes), except for the cofactor, age.
There were no statistically significant relationships between A1C level and 
gender, marital status, religion, type of diabetes, health care provider's call, height, 
weight, body mass index, blood pressures and the location of clinics where the subjects 
received their diabetes care.
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Chapter V : Discussion, Implications and Conclusion
The purpose of the study was to investigate the relationships between the response 
variable, A1C (metabolic control), and three predictor variables (hardiness, self-efficacy 
and perceived medication adherence). Another purpose was to examine for further 
refinement and for retainment of factor construct and psychometric property of the 
Perceived Medication Adherence Scale (PMAS), which was initially developed in 
summer, 2000.
The results revealed that hardiness, self-efficacy and perceived medication 
adherence were not significantly related to metabolic control. The study also further 
refined and retained the factor construct and psychometric property of the PMAS. The 
scale was found to be a one factor scale and reliable. It had good correlations with the 
HRHS and the LTMBSES.
Discussion
A1C
Of the total subjects (n = 211), 41.71% (n = 88) had A1C levels less than 7.0 %, 
which is the goal, according to the ADA (1998). This means the 58.29% (n = 123) of 
the subjects had uncontrolled diabetes. In this study, weight and BMI were not 
associated with A1C levels. The subject who weighed 105 pounds had an A1C level of
90
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7.5, whereas the subject who weighed 417.9 pounds had an A1C level of 6.2. The 
subject who had a BMI of 15.5 had an A1C level of 5.8 and the subject who had a BMI 
of 59.6 had an A1C of 6.3. The subject who had the highest A1C level (15.7) had 
overall low scores of HRHS 128, LTMBSES 76, and PMAS 75. This subject was 70 
inches tall, and weighed 187.8 pounds with a BMI of 27.
The observed mean A1C level was 7.85, whereas the predicted A1C level in the 
prediction equation was 8.70, which is higher than the observed value. This may 
explain the insignificant relationships of A1C to hardiness, self-efficacy and perceived 
medication adherence observed in the present study. A more normal distribution of 
A1C values might have supported the hypothesis that metabolic control is related to 
measures of hardiness, self-efficacy and perceived medication adherence. Although 
some subjects had good metabolic control, the majority of the subjects had uncontrolled 
A1C levels because of insulin resistance. The majority of subjects were either obese or 
morbidly obese (81%, n = 175) and had numerous chronic illnesses, such as 
hypertension, high cholesterol levels, coronary heart disease or combination of these 
abnormalities totaling 93% (n = 200).
A study similar to this study, was conducted by Schectman et al. (2002), 
included African Americans as the majority of subjects, and these subjects had a mean 
A1C level of 8.1%. In this study, the mean A1C level was 7.85, which is lower than the 
study by Schectman et al. (2002). This finding could be due to the contribution made
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by the providers' follow-up telephone calls to check on their patients and medication 
adherence — 81% (n = 174) of the subjects reported receiving the calls.
Hardiness
In this study, the subject who scored 185 (highest) on the HRHS had an A1C 
level of 5.9 % whereas the subject who scored 180 on the HRHS had an A1C level of 
9.0%. The subject who scored 94 (lowest) on the HRHS had the best metabolic control, 
A1C level of 4.8%. Thus, self-report does not support the theoretical stance. 
Self-Efficacy
According to previous studies, self-efficacy seemed to have a positive effect on 
metabolic control in patients with diabetes mellitus. In this study, the subject who 
scored 135 (highest score) on LTMBSES had an A1C of 5.8% while the subject who 
scored 51 (lowest score) on the scale had an A1C of 8.4%. Twenty-one subjects scored 
123 on LTMBSES, and their A1C levels ranged from 5.1 to 13.2. In view of this 
finding, it is tempting to conclude that self-efficacy can be transitory or has some other 
effect that has little to do with metabolic control in adults with diabetes mellitus. An 
individual's self-efficacy is related to specific situations and tasks, rather than a general 
nature (van der Bijl, van Poelgeest-Eeltink, & Shortridge-Baggett, 1999).
To examine the effect of the perceived self-efficacy and confidence in outcomes, 
selected demographic variables, and disease characteristics on an individual's adherence 
over time to a diabetes regimen (home glucose testing, medication administration, diet, 
and exercise) were studied. The study found that self-efficacy had no effect on taking
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medication, although it affected exercise, diet, and home glucose testing at different 
times. Self-efficacy appeared to be an important variable in terms of the diabetes self- 
care regimen at specific points in time, although self-efficacy appears to be unstable 
over time (Skelly et al., 1995).
Medication Adherence
The means of the PMAS (2003) score and MAS (2000) score were comparable. 
The mean of the PMAS score was 82 (SD 7.40) whereas the mean of the MAS score was 
80 (SD 8.18). Adherence to hypoglycemic medication regimens was associated with 
metabolic control in an indigent population in the study by Schectman et al. (2002). For 
each 10% increment in drug adherence, the A1C level decreased by 0.16% atp <  0.0001 
(Schectman et al., 2002). However, in the present study, 21 subjects scored 90 (highest 
score) on the PMAS and the A1C levels were from 5.2 to 12.4; the subject who scored 59 
on the scale had an A1C level of 12.8. Possibly, this result is related to insulin resistance. 
Another explanation might be a social desirability factor. Indeed, findings from this 
study revealed the apparent difficulties in correlating medication adherence to metabolic 
outcome.
Diabetes regimen adherence is a complex task and performance of any single self- 
care pattern is not strongly related to glycemic control. Further, there is no 
straightforward relationship between adherence and control. Regimen adherence does 
not automatically lead to improved metabolic control. And yet, regimen adherence
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
94
should be viewed as one of a variety of factors influencing glycemic control (Glasgow et 
al., 1987).
Metabolic control was not explained by medication adherence by provider, 
patient, and pill counts. Because sulfonylurea adherence and metabolic control both are 
influenced by numerous factors, it is not possible to accurately relate compliance and 
control (Mason et al., 1995). Adherence to the insulin regimen did not correlate 
significantly with glycemic control (Boyer et al., 1996).
Relevant Findings
There was a negative correlation between age and A1C, indicating that the older 
the adult with diabetes, the better his/her metabolic control. This finding is the same 
finding in the study conducted by (Glasgow et al., 1987). It can be postulated that after 
years of having diabetes, the older adults became accustomed to their self-care of 
diabetes, leading to better control. The positive correlation between age and duration of 
diabetes is understandable; the older the subject, the longer the duration of diabetes. In 
term of age and blood pressures, older subjects had higher systolic, and lower diastolic 
blood pressures, however, when the relationship of systolic and diastolic blood 
pressures were considered, the correlation was positive. That is, the older the subject, 
the higher the blood pressure. Older subjects reported having a religious affiliation 
more often than younger subjects. The subjects with type 2 diabetes had more 
hypoglycemic agents, both oral agents and insulin, than the subjects with type 1
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diabetes because subjects with type 1 diabetes take insulin only. The male subjects 
were taller than the female subjects, and the older subjects were shorter than the 
younger subjects. Heavy subjects had higher BMIs than their counterparts.
Implications
Nursing Implications
Participants in this study were mostly African Americans with type 2 diabetes 
mellitus. As seen in Figure 1, from the Centers for Disease Control and Prevention, 
minority populations are disproportionately affected by diabetes. Between 1980 and 
1999, the age-adjusted prevalence of diagnosed diabetes increased, and the increase was 
at a greater rate among Blacks than Whites; the age-adjusted prevalence was highest 
among black females. Furthermore, between 1997 and 1999, the age-adjusted 
prevalence of diagnosed diabetes for Hispanic males and females was similar to that of 
black males (CDC, Statistics: Diabetes Surveillance System, n.d., Retrieved March 16, 
2003) and higher in both Blacks and Hispanics than for Whites. Thus, it is reasonable 
to say that nurses taking care of patients with diabetes should pay particular attention in 
assessing the needs of patients, providing culturally sensitive education tailored to the 
patients' needs, and also providing care geared toward the prevention, and early 
detection of diabetes-related complications. Further, nurses need to actively participate 
in diabetes-related research and implement the study findings.
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Conclusion
The prevalence of diabetes mellitus is increasing. It poses a significant public 
health challenge because diabetes mellitus is a serious, complex, and costly disease.
If left uncontrolled, diabetes can cause many complications that can lead to frequent 
hospitalizations, decreased quality of life, and premature death.
The purpose of this study was to investigate the relationships between the 
response variable, A1C (metabolic control), and three predictor variables (hardiness, self- 
efficacy, and perceived medication adherence) in adults with diabetes mellitus. A cross- 
sectional correlation study was conducted. Data analyses were performed using 
correlation and multiple linear regression with hierarchical procedure. The relationships 
between A1C and the predictor variables were not statistically significant, indicating that 
each predictor variable did not contribute toward the metabolic control. The findings 
indicate that physiological phenomena were not predicted by self-reported behavioral 
phenomena.
The PMAS scale used for this study was examined for further refinement, and 
retainment of factor structure and psychometric properties. This scale was found to be of 
one factor structure and reliable.
Interestingly, age, a cofactor, was found to be correlated with metabolic control. 
Older subjects had better metabolic control than younger subjects. When age was 
compared to blood pressures, older subjects had high systolic and low diastolic blood 
pressures, however, when the blood pressures were compared with each other, a positive
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correlation was found, indicating that those who had high systolic blood pressure also 
had high diastolic blood pressure.
The study participants were mainly African Americans with type 2 diabetes 
mellitus. Research has been shown that African Americans have low adherence and self- 
management behaviors (Schectman et al., 2002). Further, the age-adjusted prevalence of 
diagnosed diabetes was higher, and increased at a greater rate among African Americans 
than Whites between 1990 and 1999 (CDC, 1998). Therefore, it is crucial to foster 
patient specific and culturally sensitive care for African Americans. Moreover, further 
testing of instruments is needed to determine if  a different norm exists for African 
Americans.
Further research is needed at different sites with different populations and multi­
center clinical trials before any generalizations are made. A randomized clinical trial 
providing diabetes regimen education and/or telephone follow-up intervention in 
conjunction with diet and medication therapy is one study project that may shed light on 
the improvement of metabolic control in adults with diabetes mellitus.
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Appendix A: Demographic Information 
MRN:   HbAic:   Date: ID #_______
BP: _______  Height:________  Weight: _______ Clinic: (DC, ACCPCC, ADWPCC)
1. Gender: 1) Female___________ 2) M ale__________
2. Age: __________
3. Race: 1) African American____________  2) Asian__________
3) Hispanic__________  4) Other__________  5) W hite__________
4. Education completed (# of years): years.
5. Marital status: 1) Single__________  2) Married__________
3) Divorced/Separated__________  4) Widowed__________
5) Committed relationship________
6. Religion: 1) Protestant____________  2) Catholic_________
3) Jewish__________  4) Islam___________  5) Other_________
7. Type of Diabetes: 1) Type 1 ____________ 2) Type 2 _______
8. My duration of diabetes is in years: __________  years
9. Diabetes medication(s) I take is(are): 1) Insulin only__________
2) Oral medication________  3) Insulin and oral medication________
10. Chronic illness(es), in addition to diabetes, I have is (are):
1) High blood pressure__________  2) Heart condition__________
3) High cholesterol__________ 4) Kidney Failure __________
5) Other__________
11. My health care provider is:
1) Physician__________  2) Nurse Practitioner__________
3) Other licensed provider___________  4) Alternative healer__________
5) Other__________
12. How often does/do your provider(s) call you to check on you for medication
taking?
1) Never__________  2) Rarely___________  3) Every 6 months______
4) Every 3 months__________ 5) Once a month________
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Appendix B: HEALTH-RELATED HARDINESS SCALE 
Instructions: ID #:
This is a questionnaire designed to determine the way in which different people view 
certain important issues related to their health. Each item is a belief statement with 
which you may agree or disagree. Beside each statement is a scale, which ranges from 
strongly disagree (1) to strongly agree (6). For each item, we would like you to circle 
the number that represents the extent to which you disagree or agree with the statement. 
Please make sure that you answer each item and that you circle only one number per 
item. Thank you for taking the time to complete this questionnaire.
1. Strongly Disagree
2. Moderately Disagree
3. Slightly Disagree
4. Slightly Agree
5. Moderately Agree
6. Strongly Agree
Circle Your Answers
13. Involvement in health promotion
activities are stimulating. 2 3 4 5 6
14. I can avoid illness if I take care of myself. 2 3 4 5 6
15. I find it difficult to be enthusiastic
about good health. 2 3 4 5 6
16. Luck plays a big part in determining
how soon I will recover from an illness. 2 3 4 5 6
17. No matter how hard I try to maintain my
health, my efforts will accomplish very little.
18. I am in control of my health.
19. I admire people who work hard to
improve their health.
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
20. Good health is more important to me than
financial security. 2 3 4 5 6
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1. Strongly Disagree
2. Moderately Disagree
3. Slightly Disagree
4. Slightly Agree
5. Moderately Agree
6. Strongly Agree
Circle Your Answers
21. My good health is largely a matter
of good fortune.
22. No matter what I do, I'm likely to get sick.
23. I find it boring to eat and exercise
properly to maintain my health.
24. The main thing which affects my
health is what I myself do.
25. Changes taking place in health
care are not exciting to me.
26. I find people who are involved
in health promotion interesting.
27. Setting goals for health is unrealistic.
28. Most things that affect my health
happen to me by accident.
29. Changes taking place in health care
will have no effect on me.
30. If I get sick, it is my own behavior
that determines how soon I get well.
31. I do not find it interesting to learn
about health.
32. I will stay healthy if it's meant to be.
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
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1. Strongly Disagree
2. Moderately Disagree
3. Slightly Disagree
4. Slightly Agree
5. Moderately Agree
6. Strongly Agree
33. I am not interested in exploring new
ways to improve my health.
34. No matter what I do, if I am going to
get sick, I will get sick.
35. I feel no need to try to maintain my
health because it makes no difference
anyway.
36. The current focus on health promotion
is a fad that will probably disappear.
37. No matter how hard I work to promote
health for society, it never seems to
improve.
38. Our society holds no worthwhile
goals or values about health.
39. If I take the right actions, I can stay
healthy.
40. I get excited about the possibility of
improving my health.
41. I am determined to be as healthy
as I can be.
Circle Your Answers
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
2 3 4 5 6
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1. Strongly Disagree
2. Moderately Disagree
3. Slightly Disagree
4. Slightly Agree
5. Moderately Agree
6. Strongly Agree
42. When my health is threatened, I view
it as a challenge that must be overcome.
43. I read everything I can about health.
44. I can be as healthy as I want to be.
45. When something goes wrong with
my health, I do everything I can to
get at the root of the problem.
46. I have little influence over my health.
Copyright, 1990, Susan E. Pollock, PhD
Circle Your Answers
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
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Appendix C: LONG-TERM MEDICATION BEHAVIOUR SELF- 
EFFICACYSCALE® (De Geest et al., 1994)
ID#:
We would like to know how much confidence you have about doing each of the 
behaviours listed below. For each of the following statements, please circle the 
number that most closely represents your level of confidence in performing the 
behaviour.
1. Very Little
2. Little
3. Neutral
4. A Lot
5. Quite A Lot
Circle Your Answers
47. Taking my medication when I am at home.
48. Taking my medication even though the pills
are big and difficult to swallow.
49. Taking my medication even though it is
very expensive.
50. Taking my medication in the absence of
medication aids (e.g. pill box, calender,...).
51. Taking my medication when nobody helps me
getting ready.
52. Taking my medication while at work.
53. Taking my medication during the weekend.
54. Taking my medication when it may cause
me to feel very hungry.
55. Taking my medication even if it drops my blood
sugar levels very low <50.
2 3 4 5
2
2
2
3
3
3
4
4
4
5
5
5
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1. Very Little
2. Little
3. Neutral
4. A Lot
5. Quite A Lot
56. Taking my medication when I feel very healthy,
57. Taking my medication when it is prescribed
to be taken every other day.
58. Taking my medication when the time of intake
does not coincide with my meal times.
59. Taking my medication when I am in
the middle of a project at home.
60. Taking my medication when it may make me
feel weak.
61. Taking my medication when nobody reminds
me about the time at which I should take the
medication.
62. Taking my medication when I have visitors
at my home.
63. Taking my medication after I have gotten
very angry at a friend.
64. Taking my medication when I am in pain.
65. Taking my medication while watching an
exiting programme on T.V.
66. Taking my medication when I feel very ill.
67. Taking my medication when I feel very sad.
Circle Your Answers
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
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1. Very Little
2. Little
3. Neutral
4. A Lot
5. Quite A Lot
Circle Your Answers
68. Taking my medication while unknown people
are watching me (e.g. in a restaurant). 1 2 3 4 5
69. Taking my medication when I feel sick in
my stomach. 1 2 3 4 5
70. Taking my medication when I am having
an argument with my partner. 1 2 3 4
71. Taking my medication when I am at
a party. 1 2 3 4
72. Taking my medication while taking
a long walk. 1 2 3 4
73. Taking my medication while visiting
a bar. 1 2 3 4
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Appendix D: Perceived Medication Adherence Scale
ID#:
Instruction: The following questions relate to hypoglycemic medication adherence. 
Please answer the questions in accordance to the scale below:
1 = Strongly disagree
2 = Disagree
3 = Slightly agree
4 = Agree
5 = Strongly agree
Circle Your Answers
74. I take my medications at the right time.
15. I take the right medications.
76. I take the right dosage of my medications.
77. I take my medications by the
prescribed method.
78. I complete the prescription as directed.
78. I comply with my health care provider's
directions regarding medications.
80. I take my medications as prescribed.
81. I know how I am supposed to take
my medications.
82. I refill my prescription before I run
out of my medications.
83. I skip my medications when I am busy.
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1 = Strongly disagree
2 = Disagree
3 = Slightly agree
4 = Agree
5 -  Strongly agree
84. I share my medications with others.
84. I read the directions on the prescription.
85. I stop taking my medications if I develop
side effects.
87. I follow the directions on the prescription.
88. I know why I take each medication.
89. I take my medications to control my
illness.
90. I adhere to my prescribed medication
routines.
91. I store all my medications as
recommended.
Circle Your Answers
3 4
3 4
3 4
3 4
3 4
2 3 4 5
2 3 4 5
1 2 3 4 5
Thank you for your participation!
Copywright, 2000, Ok Chon Allison, MSN, ANP, CDE
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The Primary Reviewer assigned to your research study is Stephanie Fox, Psy.D. If you have 
any questions, please contact Dr. Fox at sfox@vcu.edu or 827-1561; or you may contact 
Brenda frmis, IRB Coordinator, VCU Office of Research Subjects Protection, at 
binnis@hsc.vcu.edu or 828-3992.
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Appendix H.j LETTER OF INTRODUCTION
INTRODUCTION
Hello, My name is Ok Chon Allison. I have been a nurse practitioner for over 15 years, am a 
certified diabetes educator, and I currently am a doctoral (Ph.D.) student in Nursing at Virginia 
Commonwealth University, School of Nursing. As part of my dissertation work, I would like 
to learn about the relationship of diabetes control to hardiness personal characteristics, self- 
efficacy and medication adherence practice in adults with diabetes mellitus. This letter is to 
recruit adults with diabetes mellitus who are taking medication(s) for the condition to 
participate in a research project. Participation in this study involves giving permission to the 
researcher to review chart data and completing questionnaires. You are not being asked to 
participate in the educational intervention study and telephone follow-up.
BENEFITS
Your participation may also benefit you and other adults with diabetes by helping clinicians 
find out ways of promoting medication adherence. The findings of this study will be the 
foundation of conducting an interventional research project that will be focused on educational 
intervention and telephone follow-up in an attempt to facilitate diabetes medication adherence, 
thereby improving the diabetic condition and quality of lives of adults with diabetes. You will 
receive $10.00 as a recruitment incentive.
RISKS. INCONVENIENCES. DISCOMFORTS
Although there are no known physical risks to you, there is a minimal risk due to disruption of 
your flow of normal activities of daily living while you are participating in the study. The 
researcher will make every effort to create a safe environment while you complete the research 
questionnaires.
COST OF PARTICIPATION
There are no costs to you for participating in this study.
CONFIDENTIALITY
The information provided by you will remain confidential. You will be assigned a number so 
that your name will not be used in any records of the research. Absolute confidentiality cannot 
be guaranteed because of the need to give information to the sponsors, agents for the sponsors 
and an agent for the researchers and for research or regulatory purposes. The results of this 
study may be presented at meetings or in professional publications. Your identity will not be 
disclosed in those presentations.
APPROVED 
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QUESTIONS OR WITHDRAWAL
Your participation in this study is entirely voluntary. If you do participate, you may freely 
withdraw from the study at any time by notifying one of the investigators. Further, if  you have 
any questions regarding to this study now or in the future you may contact the investigators:
Janet B. Younger, Ph.D., RN, CPNP or Ok Chon Allison, MSN, ANP, CDE, 
Principal Investigator Co-investigator
E-mail: vounger@hsc.vcu.edu ocalliso@hsc.vcu.edu
Tel: (804)-828-3968 (804)-827-0100 or Cell: (804)-543-2218
Virginia Commonwealth University . Internal Medicine, VCU Health System
School of Nursing GI, Nutrition, West Hospital, 14th Floor.
1220 East Broad Street 1200 East Broad Street
Richmond, VA 23298-0567 Richmond, VA 23298-0711
APPROVED
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RESEARCH PARTICIPANT INFORMATION AND CONSENT FORM
TITLE: THE RELATIONSHIP OF METABOLIC CONTROL TO
HARDINESS, SELF-EFFICACY AND MEDICATION ADHERENCE 
IN ADULTS WITH DIABETES MELLITUS
PROTOCOL NUNBER: VCU IRB #2778
SPONSORS:
1)VCU SCHOOL OF NURSING, PHD PROGRAM
2) SIGMA THETA TAU INTERNATIONAL NURSING HONOR 
SOCIETY, GAMMA OMEGA, VCU CHAPTER
3)AMERICAN ACADEMY OF NURSE PRACTITIONERS,
FOUNDATION, DEMPSTER 2001 DOCTORAL EDUCATION NP 
RESEARCH GRANT
INVESTIGATORS:
1)JANET B. YOUNGER, PHD, RN, CPNP, PRINCIPAL INVESTIGATOR
2) OK CHON ALLISON, MSN, RN,CS, ANP, CDE, CO-INVESTIGATOR
This consent form may contain words that you do not understand. Please ask the study 
staff to explain any words or information that you do not clearly understand. You may 
keep an unsigned copy of this consent form to think about or discuss with family or friends 
before making your decision.
PURPOSE OF THE STUDY:
The purpose of this research study is to investigate the relationship between metabolic 
control, and three predictor variables - hardiness personal constellations, self-efficacy 
orientation and medication adherence practice in adults with diabetes mellitus. The 
findings may become an impetus to conduct an experimental study in the future to improve 
management and control of diabetes, which, in turn, will decrease diabetes-related 
complications, prevent or reduce hospitalizations and improve the quality of life. You are 
being asked to participate because you have been diagnosed with diabetes mellitus, taking 
medication(s) for the condition, and may meet the study entry requirements. You are not 
being asked to participate in the educational intervention study and telephone follow-up.
DESCRIPTION OF THE STUDY:
If you have agreed to participate by signing and reluming the consent form, you will be 
enrolled in this study. You will then be asked to provide demographic data and answer 
three questionnaires. Your participation in this study will require up to one hour to answer 
questionnaires. There will be no follow-ups for the study. Approximately 100 to 120 
adults with diagnosed diabetes mellitus who are taking medication(s) for the condition will 
participate in this study.
APPROVED
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PROCEDURES:
If you decide to be in this research study, you will be asked to sign this consent form after 
you have had all your questions answered. Also, your permission form will be provided 
for you to sign so that the study researchers can have access to your hospital laboratory 
Hemoglobin Aic test result and your medical record. Your blood pressure, height, and 
weight will be taken, or reviewed from your medical record. You will then be asked to 
provide demographic data and answer three questionnaires (Health-Related Hardiness 
Scale, Long-Term Medication Behavior Self-Efficacy Scale and Medication Adherence 
Scale). Each questionnaire will take about 10 to 20 minutes to complete.
RISKS AND DISCOMFORTS:
The potential risks to the participants will be minimal. There is a potential for some 
emotional discomfort for you in being asked personal questions about your background 
(age, gender, education, marital status, religion and your diabetes, etc.). If you are 
uncomfortable about answering these questions and would like to talk about them, please 
let the research investigator(s) or facilitator know. You do not have to answer any 
question(s) that you feel uncomfortable about answering. There is a minimal risk due to 
disruption of your flow of normal activities of daily living while you are participating in 
the study. The researchers will make every effort to create a safe environment while you 
complete the research questionnaires and to make sure no one sees your answers to the 
questionnaires, other than the researchers, facilitator(s) and study sponsors.
BENEFITS:
This is not a treatment study, and you are not expected to receive any direct medical 
benefits from your participation in the study. Your participation may benefit you and other 
adults wdth diabetes by helping clinicians find out ways of promoting medication 
adherence. The findings of this study will be the foundation of conducting an 
interventional research project that will be focused on educational intervention and 
telephone follow-up in an attempt to facilitate diabetes medication adherence, thereby 
improving the diabetic condition and quality of lives of adults with diabetes.
COSTS: There are no costs to you for participating in this study.
PAYMENT FOR PARTICIPATION:
You will be paid $10.00 if you complete all questionnaires.
ALTERNATIVE:
This is not a treatment study and that the alternative is not to participate. 
CONFIDENTIALITY:
The information provided by you will remain confidential. Your name will not be used. 
You will be assigned a number so that your name will not be used in any records of the 
research. Information from this study will be given to the sponsor(s). Medical records
APPROVED 2 09'30'02
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which identify you and the consent form signed by you will be looked at and/or copied for 
research or regulatory purposes by:
Absolute confidentiality cannot be guaranteed because of the need to give information to 
these parties. The results of this study may be presented at meetings or in professional 
publications. Your identity will not be disclosed in those presentations.
COMPENSATION FOR INJURY:
Virginia Commonwealth University and the VCU Health System (formerly known as 
Medical College of Virginia Hospitals) have no plan for providing long-term care or 
compensation in the event that you suffer injury as a result of your participation in this 
research study. If injury occurs, medical treatment will be available at the MCV Hospitals. 
Fees for such treatment will be billed to you or to appropriate third party insurance. Your 
health insurance company may or may not pay for treatment injuries as a result of your 
participation in this study.
VOLUNTARY PARTICIPATION AND WITHDRAWAL:
Your participation in this study is voluntary. You may decide to not participate in this 
study. If you do participate, you may freely withdraw from the study at any time by 
notifying one of the researchers during daytime hours. Your decision will not change your 
future medical care at this site or institution.
Your participation in this study may be stopped at any time by one of the study researchers 
or the sponsor(s) without your consent for medical or administrative reasons.
QUESTIONS:
In the future, you may have questions about your study participation. If you have any 
questions about the study, you may contact the investigators:
Janet B. Younger, Ph.D., RN, CPNP or Ok Chon Allison, MSN, ANP, CDE,
E-mail: vounger@,hsc.vcu.edu ocalliso@hsc.vcu.edu
• The sponsors
• An agent for the sponsor(s)
• An agent for the researchers
And may be looked at and/or copied for research or regulatory purposes by:
• The US Office o f Human Research Protections and
• Virginia Commonwealth University.
Tel: (804)-828-3968 
Virginia Commonwealth University 
School of Nursing 
1220 East Broad Street
(804)-827-0100 or Cell: 804-543-2218 
Internal Medicine, GI, Nutrition
VCU Health System 
WestHosp., 14th Floor
APPROVED
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Richmond, VA 23298-0567 1200 East Broad Street
Richmond, VA 23298-0711
If you have questions about your rights as a research participant, you may contact:
Office for Research Subjects Protection 
Virginia Commonwealth University 
1101 E. Marshall St., Room 1-023 
P. O. Box 980568 
Richmond, VA 23298 
Telephone: 804-828-0868
Do not sign this consent form unless you have had a chance to ask questions and have 
received satisfactory answers to all of your questions.
CONSENT:
I have read this consent form. I understand the information about this study. All my 
questions about the study and my participation in it have been answered; I freely consent-to 
participate in this research study.
I understand that I will receive a signed and dated copy of this consent form for my 
records.
I authorize the release of my medical records for research or regulatory purposes to the 
sponsor(s), and VCU Internal Review Board.
By signing this consent form, I have not waived any of the legal rights, which I otherwise 
would have as a subj ect in a research study.
Subject name, printed Date
Subject Signature Date
f i t  cfaru QILjm  , Hit/, 4 V P .  u)& / e - i i - o - s -
Signature of Person conducting informed consent discussion Date
(Co-Investigator)
Pmncipal Investigators Signqgjbre
APPROVED
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Permission to use Health Related Hardiness Scale 
TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER
School of Nutsiiuj 
Office of die Dean
Lubbock, Texas 79430 
(806) 743-2749
Dear Colleague;
Thank you for your interest in the Health Related Hardiness Scale (HRHS). I am happy 
to make this instrument available to you for research as a way o f collecting data from 
various populations. The requirements for using this instrument are listed below. After 1 
receive this form and a copy o f your abstract* I will mail you a copy o f the instrument.
My policy is to grant permission to use the HRHS for research purposes if I;
1. receive an abstract of the proposed research;
2. am assured of receiving the results of the study;
3. receive a copy of the reliability and validity estimates obtained;
4. am assured that no further psyohomotric analyses will be done; and
5. am credited with authorship in any use, associated report, or publication
involving the instrument,
I agree to the above requirements and have enclosed an abstract of my prcposod research.
Signed: $ 2% _^_______ Date; T ^ , i: ir r  o'7 , 2001
Mamg O k C h o n  A l l i s o n .  MSN.  ANP-  m r e ________ _ _____________________
Address: 873 7 S h a d y m is t  D r iv e ______ ;_____________ _ ________________
City & Stater Richm ond, VA 23 235   ^ -  __________________
Telephone: (work)_______________ _ ______ (home) R O A - i ___________
Sincerely
Susan E, Pollock,
Professor and Associate Dean for Research 
School o f Nursing 
Texas Tech Health Sciences Center 
3601 4th Street 
Lubbock, Texas 79430
m:\wmword\rc>ttiM<lt\hrW.dOflttact,406
An 1 X 0 /affirm ative Action Institution
,ii TV1!'''% •1 **
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Permission to use Long-Term Medication Behavior Self-Efficacy Scale
CENTRUM VOOR ZIEKENHUIS- EN VERPLEGINGSWETENSCHAP
DEPT. MAATSCHAPPELIJKE GEZONDHEIDSZORG 
FACULTEIT GENEESKUNDE 
KAPUCIJNENVOER 35 
B-3000 LEUVEN
Ok Chon Allison 
8737 Shadymist Drive 
Richmond, VA 23235 
USA
Email: oallison@vcu.org 
Tel: +1-804-7454376 
Fax:’ +1 804 7454369
ONS KENMERK 
UW KENMERK
LEUVEN, 16/07/00
Dear Dr. Ok Chon Allison,
Thank you for interest in the Long-Term Medication Behavior Self-Efficacy Scale for your research in 
diabetes mellitus patients.
The Long-Term Medication Behavior Self-Efficacy Scale has been used in two completed research 
projects on "Prevalence, determinants, and consequences of non-compliance with immunosuppressive therapy in 
transplant recipients". The first study included a sample of 150 renal transplant recipients (De Geest et al., 
Transplantation 1995; 59: 340-347) and the second study consisted of 101 heart transplant recipients (De Geest et 
al., Journal of Heart and Lung Transplantation, 1998; 17: 854-863). Self-efficacy was a determinant o f medication 
compliance behavior in both studies.
The Long-Term Medication Behavior Self-Efficacy Scale has been adjusted, based on results o f factor 
analysis and correlation analysis. The initial 33-item instrument has been reduced to a 27-item instrument. The 
Cronbach's alpha for the 27-item instrument is 0.88, reflecting good reliability (De Geest et al., Journal of Heart and 
Lung Transplantation, 1998; 17:854-863). Please find enclosed the English version of the scale.
The self-efficacy score is calculated by summing the scores o f all items divided by 27. Thus, the self- 
efficacy scores range between 1 and 5, with higher scores indicating higher levels of self-efficacy.
Items 8, 9, and 14 are related to side-effects of medication. Because the Long-Term Medication Behavior 
Self-Efficacy Scale was developed as part of a research-project in transplant recipients, the side-effects included 
are side-effects of immunosuppressive medication. We enclosed distressing symptoms related to side-effects of 
immunosuppressive therapy because these side-effects are most likely to trigger noncompliance (cf. Common 
Sense Model, Leventhal et al., Cognitive Therapy and Research 1992; 16: 143-463 & Moons, De Geest et al., 
Heart and Lung, 1998; 27: 315-325). Because these side-effects are probably not relevant for your study you could 
replace them with distressing side-effects related to the diabetes treatment under study in your research.
The Long-Term Medication Behavior Self-Efficacy Scale has been further validated based on results of 
1042 subjects who where included in several transplant compliance research projects and other studies in chronic 
patient populations worldwide. Results confirm the predictive validity of the scale. The manuscript reporting these 
findings is in preparation (Denhaerynck et al.). We are currently also in the data analysis phase of a study that 
assesses different scaling methods when using the The Long-Term Medication Behavior Self-Efficacy Scale.
Because the validation process is ongoing, I would appreciate it if you could send me your full address 
and the details of your study. Upon completion of your study l would appreciate it if you could send me the results 
concerning the Long-Term Medication Behavior Self-Efficacy Scale in case you would decide to use the scale in 
your study. This would allow us to further study psychometric properties of the instrument. I will send a copy of this 
letter to Kris Denhaerynck, one of my collaborators, who is involved in the validation studies o f the LTMBSE-scale. 
He will inform you what kind o f data we would need for further validation o f the scale should we receive 
confirmation from you that you will validate the scale.
PROF. DR. S. DE GEEST
TEL. +32-16-33 69 81 /  33 69 75FAX (016)33 69 70 
E-mail: sabina.degeest@ m ed.kuleuven.ac.be
KATHOLIEKE
UNIVERSfTEIT
LEUVEN
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Error! Reference source not found.ok chon allison 1 3 4
8737 shadymist drive 
richmond, va 23235 
usa
email: oallison@vcu.org 
tel: +1-804-7454376 
fax:’ +1 804 7454369
16/07/00
I wish you all success with your research. Please, do not hesitate if you have any further questions. 
Yours sincerely,
Sabina De Geest, Ph.D., RN, NFESC
Professor o f Nursing
D irector
Institute o f Nursing Science 
University o f Basel 
Kollegienhaus 1st Floor 
Petersplatz 1 
4003 Basel 
Sw itzerland 
Tel: +41-61-2673040 
Fax:+41-61-2670955 
Em ail: Sabina.DeGeest@ unibas.ch 
&
Center fo r Health Services and Nursing Research 
School o f Public Health 
C atholic University o f Leuven 
Kapucijnenvoer 35/4, B-3000 Leuven, Belgium 
Tel: +32-16-336975 Fax: +32-16-336970
E-m ail: Sabina.DeG eest@ m ed.kuleuven.ac.be or SdeGeest@ comDuserve.com
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Appendix L: Description of Measurements
Instrument Measures Items & Range Variable Reliability Validity
Health-Related Measures the 34 items. The 204 .91 (34 Strong support
Hardiness Scale hardiness score ranges Total item for the validity
by Susan E. construct in from 34 to 204 Scores HRHS) of the HRHS,
Pollock, 1990 health- on a six-point of 34 .87 for which is, used
related Likert-type items both the more than 250
research scale. Strongly 20-item studies
and/or the 2 disagree to commit­ internationally
dimensions strongly agree ment/ has been
of with high scores challenge established
commitment/ indicating subscale (Pollock,
challenge presence of and the 1999)
(20 items) or hardiness. 14-item
control (14 control
items). scale.
Long-Term Measures 27 items. The 135 .88 Based on
Medication Self-efficacy score ranges Total transplant
Behaviour Self- as a from 27 to 135 Scores compliance
Efficacy Scale determinant very little to of 27 research
by De Geest et of quite a lot with items projects (N =
al., 1994 medication
compliance
behavior.
higher scores 
indicating higher 
levels of self- 
efficacy.
1042) & other 
studies in 
chronic 
patients 
worldwide.
Medication Measures 18 items (19 90 .92 (Based Construct
Adherence perceived items originally). Total on the validity: Pos.
Scale (2000). medication scores range Scores original 19 Corr. between
The name of the adherence. from 18 to 90 of 18 item scale) total PMAS &
scale is changed (19 to 95 items for total subscales.
to Perceived original) on a PMAS Content
Medication five-point scale. validity: Lit.
Adherence Likert-type reviews and
Scale by scale. Strongly exam. By 6
Allison, 2003. disagree to 
Strongly agree.
nurse experts.
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